[{"text": "CRDF Stock Soars on Robust Efficacy Data From Colorectal Cancer Study Zacks Equity Research Wed, Dec 11, 2024, 6:05 PM 5 min read In This Article: ALNY +1.19% PFE -1.21% Cardiff Oncology CRDF announced robust efficacy data from an ongoing mid-stage study evaluating two doses of its lead investigational candidate, onvansertib (20 mg and 30 mg), in combination with standard-of-care (SOC) chemotherapy to treat first-line RAS-mutated metastatic colorectal cancer (mCRC) patients. The stock rallied 54.9% on Tuesday following the encouraging news. The primary endpoint of the study was objective response rate (ORR), and the secondary endpoints included progression-free survival (PFS), duration of response and safety. Per the data from the phase II CRDF-004 study, treatment with the 30 mg dose of onvansertib, a PLK1 inhibitor, demonstrated an ORR of 64%, almost double the 33% ORR observed in the control arm (SOC alone). The 30 mg dose arm also demonstrated a higher ORR compared with the 50% ORR observed in the 20 mg dose arm. Overall, patients treated with onvansertib demonstrated an ORR of 57%. The company also shared spider plots in the press release which show that patients receiving the 30mg dose of onvansertib with SOC experienced greater tumor size reduction over time compared to those in the control and 20mg dose arms with similar safety profiles for both doses. The combo therapy was also well tolerated in the CRDF-004 study with no major or unexpected toxicities observed. Based on the encouraging data readout, management believes that onvansertib has the potential to revolutionize the treatment paradigm for the first-line RAS-mutated mCRC patient population. Approximately 50,000 new patients with this mCRC indication are diagnosed in the United States, annually. In the past three months, shares of Cardiff Oncology have rallied 47.7% against the industry\u2019s 6.2% decline. Zacks Investment Research Image Source: Zacks Investment Research CRDF\u2019s Next Steps in Onvansertib Development for mCRC Cardiff Oncology expects to share additional clinical updates from the mid-stage study in the first half of 2025. Subject to positive results from the phase II CRDF-004 study, Cardiff plans to initiate a phase III CRDF-005 registrational study for the onvansertib/SOC combo to treat patients with first-line RAS-mutated mCRC. Furthermore, the FDA has also agreed with the company that an interim analysis of ORR in the planned registrational study can provide the basis for an application seeking approval for the onvansertib/SOC combo under an accelerated pathway. Under such circumstances, PFS and overall survival data will be designated as endpoints for full approval. We note that last year, Cardiff discontinued its phase II ONSEMBLE study evaluating onvansertib in combination with SOC therapy to treat patients with second-line RAS-mutated mCRC. The strategic decision was taken to focus the company's resources on its phase II CRDF-004 study in the first-line setting, where there is a higher unmet need. Story Continues Besides the mCRC indication, Cardiff Oncology is also currently evaluating the safety and preliminary efficacy of onvansertib in combination with Onyvide (nanoliposomal irinotecan), fluorouracil and leucovorin in a phase II CRDF-001 study to treat second-line patients with metastatic pancreatic ductal adenocarcinoma. CRDF Issues Underwritten Offering to Raise Funds for Operations In a separate press release, Cardiff Oncology announced the pricing of an underwritten offering of 15,384,619 shares of its common stock at an offering price of $2.60 per share, before deducting underwriting discounts and commissions. The company expects to raise approximately $40 million in gross proceeds\u00a0from the underwritten offering. Net proceeds, after deducting underwriting discounts and commissions and offering expenses, will be used to fund clinical costs for onvansertib in first-line RAS-mutated mCRC and for working capital and other general corporate purposes. The transaction is expected to close on Dec. 11, 2024, subject to the fulfillment of certain customary conditions. Cardiff Oncology, Inc. Price and Consensus Cardiff Oncology, Inc. Price and Consensus Cardiff Oncology, Inc. price-consensus-chart | Cardiff Oncology, Inc. Quote CRDF\u2019s Zacks Rank and Stocks to Consider Cardiff Oncology currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks from the drug/biotech industryare Alnylam Pharmaceuticals ALNY, Pfizer PFE and Gilead Sciences GILD, each carrying a Zacks Rank #2 (Buy) at present.\u00a0You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here . Over the past 60 days, Alnylam Pharmaceuticals\u2019 loss estimates have narrowed from 42 cents to 39 cents per share for 2024, while that for 2025 has narrowed from 47 cents to 13 cents. ALNY shares have lost 3% in the past three months. Alnylam Pharmaceuticals\u2019 earnings beat estimates in three of the trailing four quarters and matched once, delivering an average surprise of 65.67%. In the past 60 days, Pfizer\u2019s earnings estimates have risen from $2.66 to $2.92 per share for 2024, while that for 2025 has increased from $2.86 to $2.94. PFE shares have lost 12.4% in the past three months. Pfizer\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 74.50%. In the past 60 days, Gilead Sciences\u2019 earnings estimates have risen from $3.78 to $4.29 per share for 2024, while that for 2025 has increased from $7.24 to $7.38. GILD shares have risen 10.9% in the past three months. Gilead Sciences\u2019 earnings beat estimates in three of the trailing four quarters and missed the same in one, delivering an average surprise of 15.46%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Alnylam Pharmaceuticals, Inc. (ALNY) : Free Stock Analysis Report Pfizer Inc. (PFE) : Free Stock Analysis Report Gilead Sciences, Inc. (GILD) : Free Stock Analysis Report Cardiff Oncology, Inc. (CRDF) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CRDF", "date": "2024-12-11T15:05:00+00:00", "sentiment": {"score": 0.9008689001202583, "confidence": 0.9126141667366028, "probabilities": {"positive": 0.9126141667366028, "negative": 0.011745266616344452, "neutral": 0.0756404772400856}}, "embedding": [-0.010959180071949959, -0.10666336864233017, -0.07203878462314606, -0.06159026548266411, 0.015214039012789726, -0.11595980823040009, -0.12885144352912903, 0.21043577790260315, 0.14249944686889648, -0.017677681520581245, -0.06982950866222382, 0.053451504558324814, 0.11999575793743134, -0.024629712104797363, -0.07405741512775421, 0.09340521693229675, 0.06039402633905411, -0.03355387598276138, -0.1115211695432663, 0.087486132979393, -0.10788518190383911, -0.044884778559207916, 0.13172732293605804, 0.13857880234718323, -0.1531294882297516, -0.08767743408679962, -0.06202295422554016, 0.008110099472105503, -0.13742169737815857, 0.0041060131043195724, 0.11648380756378174, 0.1292223185300827, 0.08365657925605774, -0.016988631337881088, -0.08458617329597473, 0.0470852367579937, -0.0977201759815216, 0.19157449901103973, -0.1557599902153015, 0.05334454029798508, -0.06677640974521637, -0.05991207808256149, -0.04608526825904846, 0.03320486843585968, 0.024037666618824005, -0.23393383622169495, -0.08487750589847565, -0.10008086264133453, 0.027483852580189705, 0.2153729349374771, -0.10439210385084152, -0.00651470385491848, -0.10797396302223206, 0.1950838267803192, 0.06101545691490173, -0.03419975936412811, -0.1552865207195282, 0.0709783211350441, 0.034549281001091, -0.046484194695949554, -0.050726909190416336, -0.12999793887138367, -0.0034766504541039467, -0.006573110818862915, 0.14716263115406036, 0.10618306696414948, -0.015374796465039253, -0.10537508130073547, -0.02056264318525791, -0.038201041519641876, 0.058758530765771866, -0.027525965124368668, 0.030880220234394073, 0.06727010756731033, -0.11621725559234619, 0.09749795496463776, 0.16744935512542725, 0.14200058579444885, 0.06411931663751602, -0.06712841987609863, 0.05232200771570206, 0.10462749004364014, 0.13882166147232056, -0.02043040655553341, 0.0021492280066013336, 0.043741874396800995, 0.01744420826435089, 0.15685531497001648, 0.033198803663253784, 0.019308364018797874, 0.22241449356079102, 0.11728103458881378, 0.005432980600744486, 0.0033733120653778315, -0.010459640994668007, 0.004721569363027811, -0.10662885010242462, -0.08128146827220917, 0.03207514062523842, -0.00675563421100378, 0.010224733501672745, -0.049034737050533295, -0.09328913688659668, -0.09552116692066193, -0.0891304612159729, -0.08079269528388977, -0.0007031684508547187, -0.06421152502298355, -0.0590132400393486, 0.07717844098806381, 0.06884275376796722, 0.01174105517566204, -0.02191709354519844, -0.002973224502056837, -0.050298988819122314, 0.17492112517356873, -0.03503947705030441, 0.014836110174655914, 0.09000029414892197, -0.029341429471969604, 0.002032579854130745, 0.0019534570164978504, 0.02041611820459366, -0.10243932902812958, 0.050695568323135376, 0.09929805994033813, -0.022127490490674973, 1.3646672444472936e-32, -0.0419645681977272, 0.00010364409536123276, 0.10332447290420532, 0.011858752928674221, 0.009844671934843063, -0.04984557256102562, 0.11272627860307693, -0.043048687279224396, -0.07535307109355927, -0.19261744618415833, 0.038672756403684616, 0.010591594502329826, 0.04791976138949394, -0.007179396227002144, -0.14543412625789642, -0.14577263593673706, 0.03561687096953392, -0.001265854574739933, -0.16647139191627502, -0.06027941778302193, -0.009074404835700989, -0.006410318426787853, -0.059941649436950684, -0.025602739304304123, 0.004541676491498947, 0.0048850225284695625, -0.06642208993434906, 0.15004974603652954, 0.0424509271979332, 0.03318477421998978, -0.10231930017471313, -0.00603820476680994, 0.025414980947971344, -0.1153048574924469, -0.14201077818870544, -0.08125460892915726, -0.06705354899168015, -0.08969701826572418, 0.0057562533766031265, 0.05383148044347763, -0.06556911766529083, 0.02762439474463463, -0.09017595648765564, 0.028921935707330704, 0.03713541477918625, -0.1266184002161026, -0.10323235392570496, -0.0723053365945816, -0.037628524005413055, 0.057153843343257904, -0.08720583468675613, -0.034764572978019714, -0.028594864532351494, 0.0013921256177127361, -0.0936642736196518, 0.02111518755555153, -0.12352575361728668, -0.02723688632249832, 0.09269189834594727, 0.0762859359383583, 0.054923564195632935, 0.04200970008969307, 0.02569875493645668, 0.03334227576851845, -0.01692587323486805, 0.10163911432027817, -0.09040726721286774, -0.12728384137153625, -0.12259340286254883, 0.055912621319293976, -0.05286910757422447, 0.06731922924518585, 0.14405247569084167, 0.01997077278792858, 0.07040701806545258, -0.10144074261188507, 0.06672410666942596, 0.09711779654026031, 0.017009127885103226, 0.16430720686912537, -0.08966267108917236, -0.04998832568526268, -0.1270815134048462, 0.13879165053367615, -0.037120964378118515, -0.06735511124134064, -0.029790731146931648, -0.005441793240606785, -0.1118539422750473, 0.00291651813313365, 0.12529686093330383, -0.10092534124851227, -0.08783562481403351, 0.05615946277976036, 0.12212623655796051, -1.2898039765368562e-32, -0.019763989374041557, 0.06719173491001129, 0.04413125291466713, -0.007644478231668472, -0.015174150466918945, 0.07752682268619537, 0.07118234783411026, -0.0908181369304657, 0.06996966898441315, -0.11322011053562164, 0.045379169285297394, 0.17964014410972595, -0.12506411969661713, -0.07810793071985245, -0.11168324947357178, 0.04491761326789856, 0.025942031294107437, 0.0610734224319458, -0.05425889045000076, 0.020189819857478142, 0.06299257278442383, 0.11177781224250793, -0.007665978744626045, 0.03644413873553276, -0.12470648437738419, 0.10694560408592224, 0.10466732084751129, 0.05912715196609497, 0.09485366940498352, -0.0626857653260231, -0.010773327201604843, 0.06850522756576538, -0.20363231003284454, 0.03817946836352348, -0.0013662853743880987, -0.024803798645734787, 0.04391099512577057, -0.13796046376228333, -0.0984581708908081, -0.03495632857084274, 0.0440998412668705, 0.027628205716609955, -0.07526181638240814, -0.027077151462435722, -0.04950149357318878, 0.04356081783771515, 0.11455988883972168, 0.07090514898300171, 0.17882856726646423, -0.10238231718540192, -0.0830710232257843, 0.1540445238351822, -0.02383425645530224, 0.08238612115383148, 0.1426645815372467, -0.05653304606676102, 0.036406226456165314, -0.08860774338245392, -0.11049354076385498, 0.06926185637712479, -0.04170485958456993, 0.060037143528461456, -0.0716070681810379, -0.011312054470181465, 0.08257520198822021, 0.23476411402225494, -0.007114332169294357, -0.031553540378808975, 0.12718600034713745, -0.08324705064296722, -0.021470146253705025, -0.07300261408090591, 0.007707059383392334, -0.10867700725793839, -0.020638374611735344, 0.12232174724340439, 0.08255157619714737, -0.11909805238246918, -0.13768449425697327, 0.0593922883272171, -0.02107970044016838, -0.09393514692783356, 0.004840764217078686, -0.01610276848077774, -0.03594157099723816, 0.10252363979816437, -0.03134739771485329, -0.06223992258310318, 0.0005203578621149063, -0.04513326287269592, -0.02834698185324669, -0.1028064712882042, -0.0404697023332119, 0.13367187976837158, 0.07706212252378464, -1.0025147645364996e-07, 0.005330933257937431, -0.06395039707422256, 0.09532545506954193, -0.05800309032201767, 0.10075497627258301, 0.01432232465595007, -0.023776164278388023, -0.013442065566778183, -0.059038106352090836, 0.15303973853588104, 0.010932976379990578, 0.04725688323378563, -0.074153371155262, -0.02899247035384178, -0.04469093680381775, 0.03768540918827057, 0.05338277295231819, 0.013619811274111271, -0.016214584931731224, 0.06673231720924377, -0.12943881750106812, -0.12576131522655487, 0.04339125379920006, -0.06414064019918442, 0.041628990322351456, 0.035744961351156235, 0.029472388327121735, 0.10968784987926483, -0.0227920264005661, -0.016520006582140923, 0.0506209060549736, -0.1073564663529396, 0.030081745237112045, 0.12461238354444504, -0.0004531899467110634, -0.06363670527935028, 0.062711700797081, 0.09654134511947632, 0.07512776553630829, 0.20633944869041443, 0.08916954696178436, 0.011180007830262184, -0.013441042974591255, 0.06622694432735443, -0.05460015684366226, 0.03238876909017563, -0.17065474390983582, 0.004132923204451799, 0.017005376517772675, -0.14388412237167358, -0.0009216172620654106, 0.013505355454981327, -0.05482662096619606, -0.013117529451847076, -0.05147245526313782, 0.11663242429494858, -0.038465339690446854, 0.017717698588967323, 0.03234003484249115, -0.01958143711090088, 0.056621450930833817, -0.1623014658689499, -0.0027037933468818665, 0.006864722818136215], "changes": {"1wk": 21.351343601441467, "1mo": -2.432436525081473}}, {"text": "While institutions own 25% of Cardiff Oncology, Inc. (NASDAQ:CRDF), retail investors are its largest shareholders with 57% ownership editorial-team@simplywallst.com (Simply Wall St) Mon, Dec 23, 2024, 4:13 PM 4 min read In This Article: CRDF -0.50% Key Insights Significant control over Cardiff Oncology by retail investors implies that the general public has more power to influence management and governance-related decisions The top 25 shareholders own 40% of the company Recent purchases by insiders A look at the shareholders of Cardiff Oncology, Inc. ( NASDAQ:CRDF ) can tell us which group is most powerful. We can see that retail investors own the lion's share in the company with 57% ownership. Put another way, the group faces the maximum upside potential (or downside risk). Meanwhile, institutions make up 25% of the company\u2019s shareholders. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often decrease their ownership over time. Let's delve deeper into each type of owner of Cardiff Oncology, beginning with the chart below. View our latest analysis for Cardiff Oncology NasdaqCM:CRDF Ownership Breakdown December 23rd 2024 What Does The Institutional Ownership Tell Us About Cardiff Oncology? Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices. We can see that Cardiff Oncology does have institutional investors; and they hold a good portion of the company's stock. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Cardiff Oncology, (below). Of course, keep in mind that there are other factors to consider, too. NasdaqCM:CRDF Earnings and Revenue Growth December 23rd 2024 Our data indicates that hedge funds own 11% of Cardiff Oncology. That's interesting, because hedge funds can be quite active and activist. Many look for medium term catalysts that will drive the share price higher. Looking at our data, we can see that the largest shareholder is Commodore Capital LP with 11% of shares outstanding. With 5.3% and 4.7% of the shares outstanding respectively, BlackRock, Inc. and Pfizer Inc. are the second and third largest shareholders. On studying our ownership data, we found that 25 of the top shareholders collectively own less than 50% of the share register, implying that no single individual has a majority interest. Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too. Story Continues Insider Ownership Of Cardiff Oncology The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO. I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions. We can see that insiders own shares in Cardiff Oncology, Inc.. It has a market capitalization of just US$218m, and insiders have US$5.7m worth of shares, in their own names. It is good to see some investment by insiders, but it might be worth checking if those insiders have been buying. General Public Ownership The general public -- including retail investors -- own 57% of Cardiff Oncology. With this amount of ownership, retail investors can collectively play a role in decisions that affect shareholder returns, such as dividend policies and the appointment of directors. They can also exercise the power to vote on acquisitions or mergers that may not improve profitability. Public Company Ownership We can see that public companies hold 4.7% of the Cardiff Oncology shares on issue. It's hard to say for sure but this suggests they have entwined business interests. This might be a strategic stake, so it's worth watching this space for changes in ownership. Next Steps: It's always worth thinking about the different groups who own shares in a company. But to understand Cardiff Oncology better, we need to consider many other factors. For instance, we've identified 5 warning signs for Cardiff Oncology (3 make us uncomfortable) that you should be aware of. Ultimately the future is most important . You can access this free report on analyst forecasts for the company . NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CRDF", "date": "2024-12-23T13:13:32+00:00", "sentiment": {"score": -0.18289296329021454, "confidence": 0.258414626121521, "probabilities": {"positive": 0.07552166283130646, "negative": 0.258414626121521, "neutral": 0.666063666343689}}, "embedding": [0.13131052255630493, -0.14419040083885193, 0.020041506737470627, -0.06137145310640335, 0.011522969231009483, -0.0708140954375267, -0.01765008084475994, -0.0019335821270942688, 0.17346340417861938, 0.04891366884112358, -0.07367764413356781, -0.0077888136729598045, -0.029803281649947166, 0.01871570199728012, -0.10420309007167816, -0.00046586920507252216, -0.06643972545862198, -0.022721612825989723, -0.13776174187660217, 0.0981694906949997, -0.18080314993858337, -0.11992153525352478, 0.07833579927682877, 0.07832445204257965, 0.03045833855867386, -0.12445124983787537, -0.08712312579154968, 0.07035242021083832, -0.08532502502202988, -0.05150014907121658, -0.051458895206451416, 0.06077864021062851, 0.06691041588783264, 0.02749248780310154, -0.10861608386039734, -0.02572453022003174, -0.02906198427081108, 0.09071485698223114, 0.050857480615377426, 0.07181978225708008, -0.011539870873093605, 0.08152882754802704, -0.0018191495910286903, 0.003499993123114109, -0.05887628719210625, -0.1055840402841568, 0.015358446165919304, 0.03200938180088997, -0.005695926491171122, 0.08818623423576355, -0.12346871942281723, -0.024220509454607964, 0.04397311806678772, 0.010201603174209595, -0.013476097956299782, 0.11760203540325165, -0.17946788668632507, -0.01783875748515129, 0.001047041267156601, -0.00637395866215229, 0.08153921365737915, 0.10353954881429672, -0.03985552862286568, -0.014753331430256367, 0.24355864524841309, -0.002148665487766266, 0.058596767485141754, 0.07648816704750061, -0.061914823949337006, -0.04232810065150261, 0.19813086092472076, -0.18751110136508942, -0.06463473290205002, 0.07197432965040207, -0.13063356280326843, 0.09351711720228195, 0.035079218447208405, 0.1292620599269867, 0.07321196794509888, -0.097696453332901, 0.11547590792179108, 0.13673897087574005, 0.07044131308794022, -0.07278423011302948, -0.027957690879702568, -0.05653143674135208, 0.1018349826335907, 0.009943152777850628, 0.015400256961584091, 0.04791004955768585, 0.10337305068969727, -0.0009325947612524033, 0.03251093998551369, -0.03743629902601242, 0.019624002277851105, 0.03354097157716751, -0.055487386882305145, 0.031342294067144394, 0.0024050120264291763, 0.04342573508620262, 0.06213519349694252, 0.0017841989174485207, -0.13482242822647095, 0.02564079873263836, -0.08402711898088455, -0.0827932134270668, -0.012977794744074345, -0.058883920311927795, 0.0040689012967050076, 0.06608444452285767, -0.04881836101412773, 0.16971617937088013, -0.1836758255958557, -0.053077854216098785, -0.01017080619931221, 0.10478037595748901, -0.09343436360359192, 0.020778171718120575, 0.09362731128931046, -0.01903858780860901, -0.0006441250443458557, 0.020307661965489388, -0.038441456854343414, -0.09869880974292755, 0.03192071244120598, 0.12485538423061371, -0.1918971836566925, 1.1830067882815989e-32, -0.018219657242298126, 0.018768206238746643, 0.08994212746620178, -0.01798912137746811, -0.0627676397562027, -0.007644066121429205, -0.012456037104129791, -0.006313559599220753, -0.12496061623096466, -0.06514929234981537, -0.09549830108880997, 0.14165356755256653, 0.0021128077059984207, -0.22631379961967468, -0.023260727524757385, -0.09077443927526474, 0.010826904326677322, -0.024192627519369125, -0.07592552900314331, -0.031142380088567734, -0.03356344997882843, 0.20135462284088135, -0.06328781694173813, -0.06480582058429718, 0.041069090366363525, -0.22833770513534546, -0.18497496843338013, 0.10101733356714249, -0.05097807198762894, 0.10221835225820541, 0.05179673805832863, -0.05717635899782181, -0.10162094235420227, -0.14850476384162903, -0.03416731208562851, -0.09261025488376617, -0.14766190946102142, -0.045070428401231766, 0.14849978685379028, -0.0016384189948439598, -0.07998304069042206, -0.006986440159380436, -0.046695318073034286, -0.018704010173678398, -0.08144690096378326, 0.026305902749300003, -0.15660282969474792, -0.08537375926971436, -0.021198052912950516, 0.03789050877094269, -0.03469204157590866, -0.008005309849977493, -0.02197841927409172, -0.028616763651371002, 0.05951208621263504, -0.033970363438129425, 0.012244375422596931, -0.04865187406539917, 0.013152128085494041, 0.08363775908946991, 0.01219107210636139, 0.13172125816345215, -0.04389495030045509, 0.07919804751873016, -0.03831642493605614, 0.13161367177963257, 0.016755355522036552, 0.02660219371318817, -0.040991563349962234, 0.118289515376091, -0.061657629907131195, 0.10524024069309235, 0.08803297579288483, -0.09630297124385834, 0.0013910597190260887, -0.07741177082061768, -0.03269062936306, 0.11790092289447784, -0.018087290227413177, 0.1741698533296585, -0.00640749791637063, -0.07354836910963058, 0.010393450036644936, -0.010615553706884384, -0.057818032801151276, -0.029966291040182114, 0.032714176923036575, -0.008119351230561733, -0.018525658175349236, 0.08428360521793365, 0.051271360367536545, -0.10708017647266388, 0.02096487767994404, 0.15440160036087036, -0.0246367659419775, -1.1115010261106976e-32, -0.007758289575576782, -0.0912790447473526, 0.11423075199127197, -0.10162407904863358, -0.07668574154376984, -0.05510880798101425, 0.07562529295682907, -0.15427526831626892, -0.11680734157562256, -0.15135358273983002, -0.058888521045446396, 0.11079569160938263, -0.0649615079164505, 0.09316372126340866, -0.07152077555656433, 0.004971685819327831, 0.14830726385116577, -0.07652107626199722, 0.01997224986553192, -0.10769146680831909, 0.0410727821290493, 0.09599564969539642, -0.08390134572982788, 0.18448492884635925, -0.09081216156482697, 0.044821493327617645, -0.03195779025554657, 0.04132135957479477, 0.06077464297413826, -0.11986207216978073, -0.09616526961326599, -0.002286286558955908, -0.09824203699827194, 0.03769466653466225, -0.05991889536380768, -0.053574610501527786, -0.02275003120303154, -0.13856281340122223, -0.046294212341308594, 0.007556630298495293, 0.0503966361284256, 0.1035466194152832, 0.0022327667102217674, 0.0023327262606471777, 0.03750687837600708, 0.10886886715888977, 0.07081431895494461, 0.006626006215810776, 0.19075269997119904, 0.058139145374298096, 0.045274313539266586, 0.06261595338582993, 0.025799812749028206, 0.12195462733507156, 0.03967858478426933, 0.022787947207689285, 0.047253094613552094, -0.0323755145072937, -0.07333178073167801, 0.1062171533703804, 0.029260976240038872, 0.1251588612794876, -0.13520023226737976, 0.11292537301778793, -0.05740614980459213, 0.05469067394733429, -0.08957262337207794, -0.05430888384580612, 0.0034916948061436415, -0.07046423852443695, 0.006246834993362427, -0.15672174096107483, -0.019166577607393265, -0.11529110372066498, -0.1106756255030632, 0.2863560914993286, 0.06900060176849365, -0.16469255089759827, -0.09623757749795914, 0.04124533385038376, 0.0703972578048706, -0.06865879893302917, 0.06250905245542526, 0.12674817442893982, -0.050600528717041016, 0.15919256210327148, 0.025448039174079895, -0.09856334328651428, -0.008052697405219078, -0.0382247231900692, 0.10503819584846497, -0.19184432923793793, -0.007347693666815758, -0.10952834784984589, 0.044025298207998276, -1.0066107591910622e-07, 0.03145875409245491, -0.10768282413482666, 0.07523326575756073, -0.060656338930130005, 0.08313831686973572, -0.08182300627231598, 0.1376948207616806, 0.003634846769273281, 0.09829828888177872, 0.20361071825027466, 0.07255297899246216, 0.09028685837984085, -0.20174098014831543, -0.01811952330172062, -0.02553565613925457, 0.029614314436912537, -0.16869288682937622, 0.04560665413737297, -0.015839312225580215, 0.012793740257620811, 0.027482308447360992, 0.002892259508371353, 0.08336110413074493, 0.026044130325317383, -0.0006757131777703762, 0.03238328546285629, -0.005965657532215118, 0.04564154893159866, -0.02168293669819832, 0.15569642186164856, 0.08074521273374557, -0.13641470670700073, 0.05271739885210991, 0.12707938253879547, 0.04240160062909126, -0.002458753064274788, 0.08107160031795502, 0.04482932388782501, -0.026217015460133553, 0.1117887869477272, 0.04447291046380997, -0.11075244843959808, -0.041718870401382446, 0.026443466544151306, -0.005689565092325211, -0.011099542491137981, -0.12582716345787048, 0.13913843035697937, 0.10873309522867203, -0.26430386304855347, 0.11471882462501526, -0.0901639461517334, -0.01500875037163496, 0.06444812566041946, -0.04854680597782135, 0.013803472742438316, -0.093406543135643, 0.10231684148311615, -0.0872841328382492, -0.032343924045562744, 0.11660642921924591, -0.1160447895526886, 0.049931950867176056, 0.11675630509853363], "changes": {"1wk": 6.142505883432182, "1mo": -13.513517629910881}}, {"text": "Cardiff Oncology (CRDF) Reports Q3 Loss, Tops Revenue Estimates Zacks Equity Research Fri, Nov 8, 2024, 2:05 AM 3 min read Cardiff Oncology (CRDF) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.22 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 7.41%. A quarter ago, it was expected that this molecular diagnostic company would post a loss of $0.25 per share when it actually produced a loss of $0.26, delivering a surprise of -4%. Over the last four quarters, the company has surpassed consensus EPS estimates three times. Cardiff Oncology , which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $0.17 million for the quarter ended September 2024, surpassing the Zacks Consensus Estimate by 32%. This compares to year-ago revenues of $0.14 million. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Cardiff Oncology shares have added about 157.4% since the beginning of the year versus the S&P 500's gain of 24.3%. What's Next for Cardiff Oncology? While Cardiff Oncology has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Cardiff Oncology: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.27 on $0.14 million in revenues for the coming quarter and -$1.01 on $0.55 million in revenues for the current fiscal year. Story Continues Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 36% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. One other stock from the same industry, Gritstone bio Inc. (GRTSQ), is yet to report results for the quarter ended September 2024. This company is expected to post quarterly loss of $0.14 per share in its upcoming report, which represents a year-over-year change of +57.6%. The consensus EPS estimate for the quarter has been revised 64% higher over the last 30 days to the current level. Gritstone bio Inc.'s revenues are expected to be $5.6 million, up 256.7% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Cardiff Oncology, Inc. (CRDF) : Free Stock Analysis Report Gritstone bio Inc. (GRTSQ) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CRDF", "date": "2024-11-07T23:05:12+00:00", "sentiment": {"score": -0.010903477668762207, "confidence": 0.18108853697776794, "probabilities": {"positive": 0.17018505930900574, "negative": 0.18108853697776794, "neutral": 0.6487263441085815}}, "embedding": [-0.07092655450105667, -0.0033077551051974297, -0.0008295029401779175, 0.037661343812942505, -0.010308497585356236, -0.034797970205545425, -0.05426725000143051, 0.10233752429485321, 0.16856740415096283, 0.11421193182468414, -0.12592294812202454, 0.010661378502845764, -0.027092494070529938, -0.008619708009064198, -0.19918349385261536, 0.025221817195415497, -0.011926274746656418, -0.04303717985749245, -0.108243428170681, 0.029123136773705482, -0.13509517908096313, 0.05971500650048256, 0.16192132234573364, 0.13433583080768585, 0.12315286695957184, -0.07478676736354828, -0.1031455397605896, 0.1567792296409607, -0.14230240881443024, -0.07175136357545853, -0.04428984597325325, 0.1562924087047577, 0.07032233476638794, -0.09170268476009369, -0.0816437229514122, -0.0710991621017456, -0.02345556579530239, 0.1076267808675766, 0.05721643567085266, 0.06717760860919952, -0.04311593249440193, 0.034543946385383606, -0.16632848978042603, 0.03324912115931511, -0.075924813747406, -0.16186408698558807, -0.047324273735284805, -0.03716646134853363, 0.029291849583387375, 0.1289099156856537, -0.1713544875383377, -0.1166364774107933, -0.008377628400921822, 0.07992296665906906, -0.09061069041490555, 0.040322862565517426, -0.1623317301273346, -0.042026832699775696, 0.015049519017338753, 0.03245353698730469, 0.025492258369922638, 0.027713589370250702, 0.010529972612857819, 0.05395787954330444, 0.24908137321472168, 0.011257554404437542, 0.026610039174556732, 0.07229576259851456, -0.10224209725856781, 0.01136583648622036, 0.1213461309671402, -0.1038375198841095, -0.03369965776801109, 0.00647241435945034, -0.17819452285766602, 0.06049849092960358, 0.13787227869033813, 0.13505253195762634, 0.07828482985496521, -0.02235439606010914, 0.0980912297964096, -0.02989867702126503, 0.016716841608285904, -0.1049928143620491, 0.01596899889409542, -0.05245772749185562, 0.10305836796760559, 0.16030949354171753, 0.01265009306371212, 0.04283813387155533, -0.022502904757857323, -0.056726083159446716, 0.001078170957043767, -0.02368668094277382, -0.014927342534065247, 0.016789287328720093, 0.030245879665017128, -0.10677791386842728, 0.11652043461799622, 0.09652058780193329, 0.10420526564121246, 0.08391393721103668, -0.06258558481931686, -0.13220353424549103, -0.005187920294702053, -0.08129551261663437, 0.031858813017606735, -0.037798743695020676, 0.00479345116764307, 0.056718938052654266, -0.024177998304367065, 0.1375492811203003, -0.16292613744735718, -0.07863549143075943, -0.06846675276756287, 0.13871359825134277, -0.037144504487514496, 0.1061423122882843, 0.08470398187637329, 0.11169692128896713, -0.016734406352043152, 0.06691975146532059, -0.027548085898160934, -0.057732440531253815, -0.012850550934672356, 0.12325181066989899, -0.1623419225215912, 7.333940111506961e-33, 0.057894013822078705, 0.06050829589366913, 0.09547553956508636, -0.05668015778064728, -0.0014447355642914772, 0.0417444184422493, 0.03254886344075203, 0.020489389076828957, -0.07396590709686279, -0.1733943223953247, -0.13323509693145752, 0.10940662026405334, 0.059323132038116455, -0.2263723760843277, -0.029032904654741287, -0.12634415924549103, -0.031267791986465454, 0.03303464874625206, -0.10007868707180023, -0.012702670879662037, -0.03239842504262924, -0.03460575267672539, -0.06885486096143723, -0.005957326851785183, 0.04287513718008995, -0.007090386003255844, -0.09940692037343979, 0.09391553699970245, -0.11824426054954529, 0.06377532333135605, -0.0032306290231645107, -0.007761569693684578, -0.011521064676344395, -0.2370196282863617, -0.10660454630851746, -0.13413287699222565, -0.07783982902765274, -0.03404320031404495, 0.20093512535095215, 0.048072997480630875, -0.0935174971818924, 0.05885002762079239, -0.10126569867134094, -0.17195843160152435, -0.07756111025810242, 0.04094933718442917, -0.0851498395204544, -0.018480584025382996, 0.009657517075538635, 0.0007343590259552002, -0.04739506542682648, -0.05158694088459015, -0.01598730869591236, -0.04249159246683121, -0.0014298856258392334, 0.02189687266945839, -0.06574185937643051, -0.11870162189006805, 0.024541787803173065, 0.18164196610450745, 0.1497337818145752, 0.22962075471878052, 0.029047001153230667, -0.037783145904541016, -0.14531171321868896, 0.13757643103599548, -0.006109432317316532, -0.01722474955022335, -0.09918633848428726, 0.1581692397594452, -0.08304930478334427, 0.028792129829525948, 0.1888522505760193, -0.0882331058382988, 0.17053376138210297, -0.03165098652243614, -0.03325389325618744, -0.005209416151046753, 0.05894935876131058, 0.15265485644340515, 0.04461919516324997, -0.06791207194328308, -0.08105480670928955, -0.03567701578140259, 0.03909023851156235, -0.06992131471633911, 0.0636182352900505, 0.019702499732375145, -0.017953861504793167, 0.025686554610729218, 0.0643346831202507, -0.17335177958011627, -0.04787977784872055, 0.08535049855709076, 0.045222967863082886, -6.415408825774425e-33, -0.028233962133526802, 0.10918638110160828, 0.002831024117767811, -0.055284034460783005, -0.07201004028320312, -0.005227274261415005, 0.09551224112510681, 0.053517963737249374, -0.036968380212783813, -0.03106522373855114, 0.011651929467916489, 0.09315291047096252, -0.15434429049491882, 0.052631936967372894, -0.07742857933044434, 0.010398229584097862, 0.06649520993232727, -0.1426761895418167, 0.04700830578804016, -0.052167948335409164, 0.07848525047302246, 0.18138530850410461, -0.12720853090286255, 0.14594104886054993, -0.05817241221666336, 0.13209687173366547, 0.03585011512041092, 0.13650035858154297, 0.04042838513851166, -0.0786171555519104, -0.051432959735393524, -0.060426585376262665, -0.17974846065044403, 0.04558788985013962, -0.011306596919894218, -0.061273276805877686, 0.016174839809536934, -0.1659659445285797, -0.01868794858455658, -0.05260553956031799, 0.14921125769615173, 0.06807786971330643, -0.012448392808437347, 0.059676993638277054, 0.042142465710639954, 0.0473460927605629, 0.03521187603473663, 0.03563917800784111, 0.24833367764949799, -0.009970344603061676, 0.030868472531437874, 0.06080726534128189, -0.1334608495235443, 0.16988283395767212, -0.08431828022003174, 0.001602204516530037, -0.13707095384597778, -0.054835714399814606, -0.14489497244358063, 0.0545976497232914, 0.00354762957431376, 0.0873250663280487, -0.0541665256023407, 0.050573963671922684, 0.00039422884583473206, 0.12210442125797272, -0.03567724674940109, 0.009230779483914375, 0.08019185811281204, -0.05977477505803108, -0.01428295113146305, -0.04185294732451439, 0.12192101776599884, -0.14250054955482483, 0.018054643645882607, 0.282024621963501, -0.00859158020466566, -0.23019489645957947, -0.12451520562171936, 0.0580889917910099, 0.11340664327144623, -0.0510655902326107, 0.04552000015974045, 0.0660938173532486, -0.09035342931747437, 0.12675544619560242, 0.023207765072584152, -0.02982478216290474, -0.055155858397483826, -0.08311232924461365, 0.011264773085713387, -0.1711294800043106, -0.1320750117301941, 0.014697682112455368, 0.13022544980049133, -9.972936254598608e-08, 0.07319912314414978, -0.10745720565319061, 0.09962776303291321, -0.04773131012916565, 0.13722440600395203, -0.07499892264604568, 0.07397235184907913, 0.03512171283364296, 0.15191256999969482, 0.17507630586624146, -0.011702780611813068, 0.05032927542924881, -0.18461963534355164, 0.010412749834358692, -0.1107977107167244, 0.12392715364694595, -0.14854441583156586, 0.08347976207733154, 0.008163413032889366, -0.06139156594872475, -0.07518210262060165, 0.043604616075754166, 0.08303564786911011, -0.05301106721162796, 0.061598047614097595, -0.051793500781059265, -0.038823202252388, 0.06427686661481857, -0.01889582723379135, 0.015856897458434105, 0.11115062236785889, -0.09276875853538513, 0.05948811396956444, 0.1877463459968567, -0.07631371915340424, -0.18015038967132568, 0.07200546562671661, 0.0636797770857811, 0.0029105115681886673, 0.12462998926639557, 0.0265863835811615, -0.08207857608795166, -0.052353665232658386, 0.08229658007621765, -0.053020086139440536, -0.05950133875012398, -0.12248112261295319, 0.07868634909391403, 0.016357429325580597, -0.35465869307518005, 0.15860220789909363, -0.0913965255022049, 0.05075445398688316, 0.05504356324672699, 0.01728787273168564, 0.09514813125133514, -0.1519664227962494, 0.010313451290130615, -0.18754719197750092, 0.008673661388456821, 0.13880904018878937, -0.2315846085548401, 0.07654629647731781, 0.13717035949230194], "changes": {"1wk": -30.562351877362616, "1mo": -43.5207859022225}}, {"text": "Cardiff Oncology Announces Positive Initial Data from First-line RAS-mutated mCRC Clinical Trial Cardiff Oncology, Inc. Tue, Dec 10, 2024, 2:00 PM 6 min read In This Article: CRDF -0.50% Cardiff Oncology, Inc. - Initial results from randomized Phase 2 CRDF-004 trial evaluating onvansertib + standard of care in RAS-mut mCRC demonstrated 64% ORR in the 30mg onvansertib dose arm versus 33% ORR in the control arm - - In the experimental arms, 30mg dose of onvansertib demonstrated a higher ORR compared to 20mg dose of onvansertib (64% vs. 50%) with deeper tumor regression in the 30mg arm - - Onvansertib was well tolerated at both doses - - Additional clinical data from CRDF-004 trial expected in 1H 2025 - - Company will hold a conference call today at 8:00 a.m. ET / 5:00 a.m. PT - SAN DIEGO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced positive initial data from CRDF-004, a randomized, Phase 2 clinical trial evaluating onvansertib in combination with standard-of-care (SoC) in patients with first-line RAS-mutated metastatic colorectal cancer (mCRC). Efficacy and safety data are for all evaluable patients as of a November 26, 2024 data cut-off date, and all efficacy data are determined by a blinded, independent central review (BICR) of each patient\u2019s tumor scan. \u201cWe are highly encouraged by the robust efficacy signal and favorable safety profile observed with onvansertib plus standard-of-care from the first 30 evaluable patients in our randomized first-line RAS-mutated mCRC CRDF-004 trial,\u201d said Fairooz Kabbinavar, MD, FACP, Chief Medical Officer of Cardiff Oncology. \u201cOur data shows an objective response rate of 64% in patients receiving the 30 mg dose of onvansertib in combination with standard of care, significantly higher than the 33% objective response rate observed in the control arms of standard of care alone. In addition, as can be seen in the spider plots, we are observing deeper tumor response in patients receiving the 30mg dose of onvansertib compared to those receiving the 20mg dose with similar safety profiles for both doses.\u201d Study Design The CRDF-004 phase 2 trial is currently enrolling patients with mCRC who have a documented KRAS or NRAS mutation. Onvansertib is added to SoC consisting of FOLFIRI plus bevacizumab or FOLFOX plus bevacizumab. Patients are being randomized in a 1:1:1 ratio to either 20mg of onvansertib plus SoC, 30mg of onvansertib plus SoC, or SoC alone. The primary endpoint is objective response rate (ORR), and the secondary endpoints include progression-free survival (PFS), duration of response (DOR) and safety. Efficacy Data Objective Response Rates observed in the CRDF-004 clinical trial, as of the data cut-off date of November 26, 2024, are shown below. Story Continues Control Arm (SoC alone) 20mg dose of onvansertib + SoC 30mg dose of onvansertib + SoC All onvansertib patients 33% ORR (3 of 9) 50% ORR (5 of 10) 64% ORR (7 of 11) 57% ORR (12 of 21) Spider Plots, displaying the change in tumor size from baseline for each patient over time, demonstrate deeper responses observed in patients receiving the 30mg dose of onvansertib in combination with the SoC compared to both the control arms and 20mg dose of onvansertib arms. Note: Radiographic response determined per RECIST 1.1 by blinded independent central review. Spider plot reflects interim data as of November 26, 2024 from an ongoing trial and unlocked database. Note: Radiographic response determined per RECIST 1.1 by blinded independent central review. Spider plot reflects interim data as of November 26, 2024 from an ongoing trial and unlocked database. Safety and Tolerability Onvansertib in combination with chemo/bevacizumab was well-tolerated and there have been no major or unexpected toxicities observed. \u201cOverall, these data support our belief that onvansertib has potential to change the treatment paradigm for the entire first-line RAS-mutated mCRC patient population of almost 50,000 new patients diagnosed in the U.S. annually,\u201d said Mark Erlander, Chief Executive Officer of Cardiff Oncology. \u201cIn addition to the efficacy signal observed, the data demonstrate that onvansertib can safely be combined with the two different chemo backbones that are currently approved as standard of care in the first-line setting, thus providing a key differentiated profile over previous generation PLK1 inhibitors. We look forward to providing additional clinical updates from our CRDF-004 trial in the first half of 2025.\u201d Upcoming expected milestones Additional clinical data from CRDF-004 trial expected in 1H 2025 Conference Call and Webcast Cardiff Oncology will host a conference call and live webcast at 8:00 a.m. ET / 5:00 a.m. PT on December 10, 2024. Individuals interested in listening to the live conference call may do so by using the webcast link in the \" Events \" section of the company's website. A webcast replay will be available in the investor relations section on the company's website following the completion of the call. About Cardiff Oncology, Inc. Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers. The Company's lead asset is onvansertib, a PLK1 inhibitor being evaluated in combination with standard of care (SoC) therapeutics in clinical programs targeting indications such as RAS-mutated metastatic colorectal cancer (mCRC), as well as in ongoing and planned investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC) and triple negative breast cancer (TNBC). These programs and the Company's broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to SoC alone. For more information, please visit https://www.cardiffoncology.com . Forward-Looking Statements Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified using words such as \"anticipate,\" \"believe,\" \"forecast,\" \"estimated\" and \"intend\" or other similar terms or expressions that concern Cardiff Oncology's expectations, strategy, plans or intentions. These forward-looking statements, including statements regarding Cardiff Oncology\u2019s plans to provide additional clinical updates from our CRDF-004 trial in the first half of 2025, are based on Cardiff Oncology's current expectations and actual results could differ materially. There are several factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; our clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product candidate; results of preclinical studies or clinical trials for our product candidate could be unfavorable or delayed; our need for additional financing; risks related to business interruptions, including the outbreak of an epidemic or pandemic such as the COVID-19 coronavirus and cyber-attacks on our information technology infrastructure, which could seriously harm our financial condition and increase our costs and expenses; uncertainties of government or third party payer reimbursement; dependence on key personnel; limited experience in marketing and sales; substantial competition; uncertainties of patent protection and litigation; dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. There are no guarantees that our product candidate will be utilized or prove to be commercially successful. Additionally, there are no guarantees that future clinical trials will be completed or successful or that our product candidate will receive regulatory approval for any indication or prove to be commercially successful. Investors should read the risk factors set forth in Cardiff Oncology's Form 10-K for the year ended December 31, 2023, and other periodic reports filed with the Securities and Exchange Commission. While the list of factors presented here is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Forward-looking statements included herein are made as of the date hereof, and Cardiff Oncology does not undertake any obligation to update publicly such statements to reflect subsequent events or circumstances. Cardiff Oncology Contact: James Levine Chief Financial Officer 858-952-7670 jlevine@cardiffoncology.com Investor Contact: Kiki Patel, PharmD Gilmartin Group 332-895-3225 Kiki@gilmartinir.com Media Contact: Grace Spencer Taft Communications 609-583-1151 grace@taftcommunications.com A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/22880436-fc66-4f63-8937-5e69de0ce613 View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CRDF", "date": "2024-12-10T11:00:00+00:00", "sentiment": {"score": 0.6328948242589831, "confidence": 0.6483676433563232, "probabilities": {"positive": 0.6483676433563232, "negative": 0.015472819097340107, "neutral": 0.33615946769714355}}, "embedding": [-0.06097624450922012, -0.09668391942977905, -0.04007694870233536, -0.0694388747215271, 0.02402305416762829, -0.22878128290176392, -0.10616692900657654, 0.14960318803787231, 0.15217195451259613, -0.011723561212420464, -0.13173599541187286, 0.012172793969511986, 0.18926787376403809, -0.026248347014188766, -0.08125755935907364, 0.18077000975608826, 0.10885980725288391, 0.0519985668361187, -0.12023340910673141, 0.13140259683132172, -0.046787623316049576, -0.031250372529029846, 0.06266342103481293, 0.1476745903491974, -0.11428805440664291, -0.1323992758989334, -0.09087586402893066, 2.1824787836521864e-05, -0.2018502652645111, -0.030375637114048004, 0.09845113754272461, 0.058742210268974304, 0.038710206747055054, 0.009235402569174767, -0.09514082223176956, 0.04455596208572388, -0.16751763224601746, 0.20232054591178894, -0.16000327467918396, 0.01404306199401617, -0.04986023157835007, -0.0019526728428900242, -0.00029339082539081573, 0.012347185052931309, 0.02941204234957695, -0.17902909219264984, -0.07150059938430786, -0.11787451058626175, -0.002700507640838623, 0.30587074160575867, -0.05527852103114128, 0.040250055491924286, -0.1816076934337616, 0.24910032749176025, 0.09696242958307266, -0.07310259342193604, -0.13946878910064697, 0.08422619104385376, 0.03346047177910805, 0.04088951274752617, -0.04311295598745346, -0.16136127710342407, -0.01995951309800148, -0.021738804876804352, 0.07188770920038223, 0.06204109266400337, -0.1090170219540596, -0.11358591914176941, -0.06570535153150558, -0.07715815305709839, 0.05648289620876312, 0.0022987741976976395, 0.03385895490646362, 0.09047868847846985, -0.08468888700008392, 0.01684189774096012, 0.2145080417394638, 0.20101621747016907, 0.10779429227113724, -0.022562479600310326, 0.006743315607309341, 0.11529362201690674, 0.1306615173816681, -0.0746561735868454, 0.021793857216835022, 0.06495150923728943, 0.039260510355234146, 0.2036380171775818, 0.11579494178295135, 0.04107636585831642, 0.26199471950531006, 0.21323993802070618, 0.005027580074965954, 0.036048900336027145, 0.06664294004440308, -0.06762434542179108, -0.06773734837770462, -0.05686670541763306, -0.018303044140338898, 0.04611748456954956, -0.013532583601772785, -0.01874632015824318, -0.07365381717681885, -0.05551120266318321, -0.05806772783398628, -0.11309053003787994, 0.027141042053699493, -0.13890844583511353, -0.04000212252140045, 0.05560768023133278, 0.15253101289272308, 0.019598480314016342, 0.00033342838287353516, 0.06517751514911652, -0.07300254702568054, 0.15383285284042358, -0.037380218505859375, -0.022814996540546417, 0.09077229350805283, -0.03534854203462601, -0.016671303659677505, 0.06570272892713547, 0.05935019999742508, -0.0912630707025528, 0.04890121519565582, 0.18084225058555603, -0.06114570051431656, 1.3229877412501878e-32, -0.07643479108810425, -0.008062144741415977, 0.10065621137619019, 0.00449824333190918, 0.0037053367123007774, -0.07578148692846298, 0.10217231512069702, 0.00787881575524807, -0.08206361532211304, -0.141457200050354, -0.03574496880173683, 0.01981709711253643, 0.040543973445892334, 0.04255666956305504, -0.09320972859859467, -0.0818769782781601, 0.03552086278796196, -0.02393963746726513, -0.1574822962284088, -0.061289384961128235, -0.022682800889015198, -0.013709599152207375, -0.08943109214305878, -0.07137927412986755, -0.06860680878162384, -0.037988267838954926, -0.02245541289448738, 0.10731427371501923, 0.06097730994224548, 0.03420054167509079, -0.21294158697128296, -0.019504941999912262, 0.11612775921821594, -0.062252774834632874, -0.1281762421131134, -0.10076074302196503, -0.0610261932015419, -0.06346739083528519, -0.03541084751486778, 0.08782163262367249, -0.03778568282723427, -0.022487822920084, -0.1221083253622055, 0.031565502285957336, 0.04277856647968292, -0.15276682376861572, -0.058492258191108704, -0.0564940944314003, -0.020260903984308243, 0.05653093382716179, -0.11079923808574677, -0.05900594964623451, -0.02713622897863388, 0.07791391015052795, -0.13003967702388763, 0.0018803743878379464, -0.13853353261947632, 0.01801840402185917, 0.0939941555261612, 0.10591581463813782, 0.0012184586375951767, -0.004296154715120792, 0.07502777129411697, 0.008255974389612675, 0.008212164044380188, 0.10903525352478027, -0.145564466714859, -0.08578410744667053, -0.10198667645454407, 0.045982956886291504, -0.047865018248558044, -0.008707672357559204, 0.13879680633544922, 0.07369407266378403, 0.0571371391415596, -0.07415822893381119, 0.11620576679706573, 0.11044347286224365, 0.014460228383541107, 0.21086104214191437, -0.0679233968257904, 0.04696773737668991, -0.18362301588058472, 0.130447655916214, -0.07142604887485504, -0.15276378393173218, -0.03468707576394081, -0.0668230801820755, -0.13322807848453522, 0.03930962085723877, 0.09452073276042938, -0.09471427649259567, -0.10127778351306915, 0.045927584171295166, 0.09011000394821167, -1.2287292573615641e-32, 0.012519123032689095, 0.07690419256687164, 0.010650585405528545, 0.016524240374565125, -0.01800556294620037, 0.10894431173801422, 0.12155406922101974, -0.17298421263694763, 0.060663774609565735, -0.17544563114643097, 0.03162527084350586, 0.11918673664331436, -0.10557162016630173, -0.07334493100643158, -0.07017840445041656, 0.015913356095552444, -0.03375846520066261, 0.059143275022506714, -0.11835908889770508, 0.14201697707176208, 0.09507229179143906, 0.16604535281658173, 0.008288802579045296, -0.03253486007452011, -0.17207983136177063, 0.05893609672784805, 0.12324683368206024, 0.11462821811437607, 0.1762068271636963, -0.06468627601861954, -0.04428990185260773, 0.06302003562450409, -0.21275852620601654, 0.03350670635700226, -0.01421352569013834, 0.017022784799337387, 0.1302793323993683, -0.12862911820411682, -0.0605999119579792, -0.02282125875353813, 0.05664330720901489, 0.03758477419614792, -0.14795704185962677, 0.017679966986179352, -0.024940581992268562, 0.06228145584464073, 0.0679534450173378, 0.07530578225851059, 0.15907910466194153, -0.139946848154068, -0.09557246416807175, 0.1048429012298584, 0.007691358216106892, 0.03163637965917587, 0.07984286546707153, -0.13379442691802979, 0.05022241920232773, -0.05050186067819595, -0.09729273617267609, 0.0704461857676506, -0.028192248195409775, 0.028573770076036453, -0.05699312686920166, -0.026466170325875282, 0.0653320774435997, 0.2929404079914093, 0.04774957895278931, -0.022279035300016403, 0.07514292746782303, -0.03833349421620369, -0.13827155530452728, -0.09647591412067413, -0.008907943964004517, -0.11656318604946136, -0.004977229982614517, 0.14042210578918457, 0.13522274792194366, -0.11609809100627899, -0.10142072290182114, -0.018184371292591095, -0.021152134984731674, -0.07721499353647232, -0.03283526375889778, -0.061942070722579956, 0.031218741089105606, 0.12308941036462784, -0.02104244753718376, -0.07667803764343262, 0.034415822476148605, 0.028204411268234253, -0.08070512115955353, -0.11114634573459625, -0.08734164386987686, 0.1898908019065857, -0.009017190895974636, -9.994788285894174e-08, 0.05134720355272293, -0.09090358018875122, 0.10105656832456589, -0.09088429808616638, 0.061936795711517334, 0.06352855265140533, -0.09732969105243683, -0.0008801289368420839, -0.11789201945066452, 0.10051294416189194, 0.10031694173812866, 0.06273864209651947, -0.08067820966243744, -0.058944929391145706, -0.009363768622279167, 0.06204632669687271, 0.025085696950554848, -0.015444591641426086, 0.030393308028578758, 0.09963963180780411, -0.129518523812294, -0.10154706239700317, 0.04277585819363594, -0.07208722829818726, 0.08862830698490143, -0.01768874190747738, -0.008511834777891636, 0.13252758979797363, -0.030496034771203995, -0.02631593495607376, 0.07062329351902008, -0.08086912333965302, 0.04971303045749664, 0.08848347514867783, 0.0372387133538723, -0.07599075138568878, 0.021512478590011597, 0.09916031360626221, 0.13099020719528198, 0.18602582812309265, 0.12436343729496002, 0.04999460652470589, -0.0784272849559784, 0.03166360408067703, -0.06120384857058525, 0.031009506434202194, -0.1952456831932068, -0.07682362198829651, 0.055970512330532074, -0.12135779857635498, -0.018924517557024956, 0.027560871094465256, 0.0027284640818834305, -0.025148488581180573, -0.003159712767228484, 0.09276808053255081, -0.0524255633354187, -0.07247862219810486, 0.03110695630311966, -0.03114316053688526, 0.056354403495788574, -0.10349757969379425, -0.0018576700240373611, -0.03629392385482788], "changes": {"1wk": 6.613762971184969, "1mo": 3.4391564927213896}}, {"text": "PREMIUM Cardiff Oncology Reports High Tumor Response in Mid-Stage Onvansertib Trial; Shares Rise Pre-Bell MT Newswires Tue, Dec 10, 2024, 2:52 PM 1 min read Cardiff Oncology (CRDF) said Tuesday that preliminary results from a mid-stage study of its cancer t PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CRDF", "date": "2024-12-10T11:52:44+00:00", "sentiment": {"score": 0.1133940452709794, "confidence": 0.12303180247545242, "probabilities": {"positive": 0.12303180247545242, "negative": 0.009637757204473019, "neutral": 0.8673303723335266}}, "embedding": [-0.09429050236940384, -0.044972386211156845, 0.03919873759150505, 0.005419083405286074, 0.06475570052862167, -0.08889668434858322, -0.11583211272954941, 0.06452804803848267, -0.02212432213127613, 0.039398882538080215, -0.11574247479438782, 0.06981948018074036, 0.02394356019794941, -0.0619673989713192, -0.07237933576107025, 0.06611883640289307, 0.035114556550979614, -0.2249504029750824, 0.05389757826924324, 0.016757410019636154, -0.2788393497467041, 0.010599859990179539, 0.19318702816963196, 0.16145916283130646, 0.06542269885540009, -0.17934784293174744, -0.18662166595458984, 0.1201619803905487, -0.03471431881189346, 0.027348250150680542, 0.02815430611371994, 0.006137204822152853, -0.11842198669910431, -0.05103900283575058, -0.09571543335914612, -0.03881891071796417, -0.10174120217561722, 0.08264652639627457, -0.17043046653270721, 0.11288798600435257, 0.04400136321783066, -0.14564648270606995, -0.17418992519378662, 0.13139696419239044, -0.014247757382690907, -0.10391180217266083, -0.13257110118865967, -0.11059127002954483, -0.016502508893609047, 0.15973761677742004, -0.09300790727138519, -0.11511695384979248, -0.06364854425191879, 0.00298310536891222, -0.03826165199279785, -0.027968352660536766, -0.24207018315792084, 0.05581463500857353, -0.013406326994299889, -0.12888582050800323, 0.0096215158700943, -0.07498374581336975, -0.11775472015142441, 0.07036919891834259, 0.15185397863388062, 0.1855374276638031, 0.022460006177425385, 0.10871955752372742, 0.06532961875200272, -0.14468885958194733, 0.12922403216362, -0.053920257836580276, -0.004933871794492006, 0.11488083004951477, -0.04249707981944084, 0.04962516576051712, 0.15124526619911194, 0.025623584166169167, 0.05730510130524635, -0.02535879611968994, 0.023149942979216576, -0.0002747729595284909, 0.13205140829086304, -0.05696966499090195, 0.013834959827363491, -0.09006808698177338, 0.011389785446226597, 0.056933168321847916, -0.06920976936817169, -0.0013573491014540195, 0.24450825154781342, 0.00394591735675931, -0.1325879544019699, 0.15673214197158813, -0.2678409814834595, -0.04329827427864075, -0.00417311629280448, -0.1441907286643982, 0.0065403594635427, 0.10552601516246796, 0.013689116574823856, 0.010677523910999298, -0.02978207729756832, -0.02537606470286846, -0.09099533408880234, -0.054558444768190384, -0.01175328902900219, -0.0005416666390374303, -0.11181247979402542, 0.01996399648487568, 0.054128777235746384, 0.14024725556373596, 0.09301592409610748, -0.13036319613456726, -0.03215431049466133, 0.17242342233657837, -0.21535298228263855, 0.03268853947520256, 0.020478544756770134, -9.633819718146697e-05, -0.07141853868961334, -0.008049139752984047, -0.16375966370105743, -0.05977315083146095, 0.044536661356687546, 0.2255929410457611, -0.08801539242267609, 1.4605505554023414e-32, 0.02295883372426033, -0.017206287011504173, 0.1626989096403122, 0.024512529373168945, 0.011522564105689526, 0.04995366930961609, 0.02991703897714615, -0.041994836181402206, -0.17371582984924316, -0.2136552929878235, -0.09475047886371613, 0.015433380380272865, 0.0680951252579689, -0.19076143205165863, -0.3279701769351959, -0.20453312993049622, -0.05419773980975151, 0.05086497217416763, -0.140425905585289, 0.0669146403670311, -0.08571724593639374, -0.07110826671123505, -0.12995365262031555, -0.07059759646654129, -0.0541485957801342, -0.013109053485095501, 0.020045695826411247, 0.1480647176504135, 0.03725311532616615, 0.15159103274345398, -0.24240140616893768, -0.011650696396827698, 0.014607992023229599, -0.14037945866584778, -0.11758199334144592, 0.02978958562016487, -0.06251722574234009, -0.07196806371212006, 0.08094184100627899, -0.07078807055950165, 0.0024843530263751745, -0.038007814437150955, -0.09785933047533035, -0.031175551936030388, -0.05027153715491295, -0.025516660884022713, -0.09230802208185196, -0.15489619970321655, -0.007584135979413986, -0.017658669501543045, -0.04700186103582382, -0.0314205177128315, -0.15980517864227295, 0.03928619623184204, -0.05175676941871643, 0.1090468019247055, -0.026885895058512688, 0.0025726750027388334, 0.1330195665359497, 0.09879951179027557, 0.26927807927131653, 0.009463281370699406, 0.013846006244421005, -0.09141592681407928, -0.044428449124097824, 0.0362444631755352, -0.1695631593465805, -0.2633228600025177, -0.11810468137264252, 0.06017957627773285, 0.06476633250713348, 0.08760175108909607, 0.21099169552326202, -0.026988903060555458, 0.05536535009741783, 0.08232171088457108, 0.025155657902359962, 0.05156102776527405, 0.10363683849573135, 0.25619906187057495, 0.04961641505360603, -0.1510210931301117, -0.07857176661491394, -0.007230052258819342, 0.1172180026769638, -0.09028677642345428, 0.002360544167459011, -0.13623760640621185, -0.04439254850149155, 0.0507170706987381, 0.11095143854618073, -0.04561959207057953, -0.013999085873365402, 0.04687347263097763, 0.04983831197023392, -1.372997238227602e-32, 0.07256005704402924, 0.06195521354675293, 0.04598921164870262, -0.10719533264636993, -0.03490818664431572, 0.12050813436508179, -0.013043082319200039, 0.06695367395877838, 0.04847677797079086, 0.12410444766283035, 0.1368739753961563, 0.11169564723968506, -0.10046416521072388, -0.07965864986181259, 0.004677671939134598, -0.09424411505460739, 0.18194444477558136, -0.09775206446647644, -0.020770838484168053, 0.01813872903585434, 0.01799396052956581, 0.1648026406764984, -0.137101948261261, 0.1453736573457718, -0.11346236616373062, 0.06803160160779953, 0.05703271925449371, 0.15587744116783142, 0.03251984715461731, -0.10973849892616272, -0.0805758610367775, -0.05166303366422653, -0.12641993165016174, 0.078932985663414, 0.007522835396230221, 0.025896349921822548, 0.27444347739219666, -0.08475950360298157, -0.06530258059501648, -0.055549368262290955, 0.07577076554298401, -0.042387522757053375, -0.14631888270378113, 0.06003708764910698, 0.037019308656454086, 0.11288144439458847, -0.019567230716347694, -0.016822146251797676, 0.2411707490682602, -0.0806182473897934, 0.030642343685030937, 0.18729090690612793, -0.003058822825551033, 0.10513283312320709, 0.02536555379629135, -0.049022648483514786, -0.07677479833364487, -0.10932262986898422, -0.06748933345079422, 0.06404489278793335, 0.07673285901546478, 0.02916492521762848, -0.24545137584209442, -0.0869721844792366, 0.10750563442707062, 0.22285142540931702, 0.02184181474149227, -0.029537325724959373, 0.18619383871555328, 0.027403293177485466, -0.14565522968769073, 0.004905561450868845, -0.07234947383403778, -0.22618097066879272, 0.05085377395153046, 0.12771107256412506, 0.07938825339078903, -0.07114661484956741, -0.09508073329925537, 0.0786643773317337, 0.03613737225532532, -0.1383170783519745, 0.06938790529966354, 0.010889220982789993, 0.02972201444208622, 0.06405586749315262, 0.007802869193255901, -0.055068571120500565, -0.11782027781009674, 0.0025070407427847385, 0.006820060312747955, -0.043518420308828354, -0.10458741337060928, 0.1855008602142334, 0.16387708485126495, -1.0008338335865119e-07, 0.07148120552301407, -0.18104535341262817, 0.07038144767284393, 0.02788863144814968, 0.09486424177885056, -0.02394741214811802, -0.04198797419667244, 0.12640543282032013, -0.004038214683532715, 0.1916217803955078, -0.05075589567422867, 0.0012471365043893456, 0.038070883601903915, -0.09471157193183899, 0.06932464987039566, 0.0973854586482048, -0.0643097385764122, 0.025274429470300674, -0.0471668615937233, -0.013750464655458927, 0.07491906732320786, 0.0447089821100235, 0.1843891441822052, -0.043953780084848404, 0.05446169525384903, 0.06404214352369308, 0.0409783311188221, 0.17171329259872437, -0.03584001213312149, -0.1144975796341896, -0.02141565829515457, -0.1129818931221962, -0.11901739984750748, 0.13306233286857605, -0.00821908749639988, -0.020771462470293045, 0.12675043940544128, 0.0673362985253334, 0.1029094010591507, 0.15085306763648987, 0.07279282808303833, -0.05387650057673454, -0.017949769273400307, 0.15412218868732452, -0.08595423400402069, 0.04953556880354881, -0.13855713605880737, 0.03331032022833824, 0.08364256471395493, -0.2689138352870941, 0.1071440652012825, -0.05324268341064453, 0.06072818115353584, 0.056213896721601486, -0.07531199604272842, 0.18532411754131317, -0.033440254628658295, 0.045594166964292526, -0.053353603929281235, 0.10311588644981384, 0.22213205695152283, -0.18639743328094482, 0.02371670864522457, 0.053392961621284485], "changes": {"1wk": 6.613762971184969, "1mo": 3.4391564927213896}}, {"text": "Cardiff Oncology Reports Promising Phase 2 Trial Results TipRanks Wed, Dec 11, 2024, 3:19 PM 1 min read In This Article: CRDF -0.50% https://www.tipranks.com/news/the-fly/intuitive-surgical-price-target-raised-to-622-from-561-at-btig An update from Cardiff Oncology ( (CRDF) ) is now available. Pick the best stocks and maximize your portfolio: Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks! Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks Cardiff Oncology has reported promising initial results from its Phase 2 trial (CRDF-004) testing onvansertib with standard care in first-line RAS-mutated metastatic colorectal cancer. The data suggests enhanced efficacy with onvansertib, showing higher overall response rates compared to standard treatments alone. This development could represent a significant breakthrough for investors watching the oncology sector, though risks and uncertainties remain as the trials progress. Learn more about CRDF stock on TipRanks\u2019 Stock Analysis page . Trending Articles Shareholder Alert for Dentsply Sirona, Inc. (NASDAQ:XRAY) Shareholder Alert for Warner Bros. Discovery, Inc. (NASDAQ:WBD) 3 Penny Stocks to Watch Now, 12/10/24 View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CRDF", "date": "2024-12-11T12:19:54+00:00", "sentiment": {"score": 0.22325866483151913, "confidence": 0.2337060123682022, "probabilities": {"positive": 0.2337060123682022, "negative": 0.010447347536683083, "neutral": 0.7558466196060181}}, "embedding": [-0.08580335974693298, -0.170714870095253, -0.04299270361661911, -0.053627997636795044, 0.06195924058556557, -0.08224242180585861, -0.06610747426748276, 0.12806986272335052, -0.0057817683555185795, 0.05020635202527046, -0.08170080184936523, 0.04756637290120125, 0.01643964648246765, 0.03300590440630913, -0.1764802187681198, 0.03192799910902977, 0.04674775153398514, -0.11676884442567825, -0.04828726127743721, 0.03378954902291298, -0.18702101707458496, -0.0709073394536972, 0.18062014877796173, 0.1541951298713684, 0.001263223122805357, -0.11089059710502625, -0.08111182600259781, 0.06843923777341843, -0.08659758418798447, -0.03355281054973602, 0.06579726189374924, 0.07129428535699844, -0.00804163422435522, -0.06840619444847107, -0.06935887038707733, -0.006032551638782024, 0.014470665715634823, 0.12128367274999619, -0.07102856785058975, 0.06092764809727669, -0.00858918484300375, -0.13139842450618744, -0.15702061355113983, 0.0879860371351242, 0.0798729956150055, -0.216151624917984, -0.03531423956155777, -0.09130030870437622, 0.044821884483098984, 0.18187427520751953, -0.19719929993152618, -0.06794063001871109, 0.008361621759831905, 0.04772639274597168, -0.005332348868250847, -0.0025944309309124947, -0.16588133573532104, -0.04293140396475792, 0.049435582011938095, -0.0263095460832119, 0.03180338069796562, -0.1586102843284607, 0.06271760910749435, -0.005411847960203886, 0.14436069130897522, 0.015346651896834373, -0.0026235810946673155, -0.0314980186522007, 0.025850223377346992, -0.046160727739334106, 0.054402630776166916, -0.058356162160634995, 0.08917379379272461, 0.05702105909585953, -0.058144956827163696, 0.09410092979669571, 0.1399044394493103, 0.06649108976125717, 0.10624202340841293, -0.019986730068922043, 0.02282024547457695, 0.0223842766135931, 0.18646469712257385, -0.0018982762703672051, -0.010964479297399521, -0.05447157099843025, 0.04913102090358734, 0.0874033197760582, -0.0434245839715004, 0.031954679638147354, 0.19812700152397156, 0.0782533809542656, 0.0002897058438975364, 0.06418878585100174, -0.01826576702296734, 0.028338830918073654, -0.1112668439745903, -0.14003902673721313, 0.037579141557216644, -0.014097778126597404, 0.016971657052636147, 0.021435990929603577, -0.14436978101730347, -0.1373244822025299, -0.058005452156066895, -0.13387072086334229, 0.019992638379335403, -0.03849789500236511, 0.006512609776109457, 0.024205731227993965, 0.04197600111365318, 0.2037050575017929, -0.0175975039601326, -0.039572134613990784, -0.0982370525598526, 0.1909751147031784, -0.09879262745380402, 0.0139900092035532, 0.14214801788330078, -0.018879687413573265, -0.01967843994498253, -0.013267889618873596, -0.05560656264424324, -0.1452418863773346, 0.1014346182346344, 0.15648922324180603, -0.12484384328126907, 1.047489407768273e-32, 0.019238490611314774, 0.1421295702457428, 0.06461957842111588, 0.010902293026447296, -0.07862275838851929, 0.005236683413386345, 0.03449917584657669, -0.010613593272864819, -0.1694413274526596, -0.17921967804431915, -0.014715389348566532, 0.009120137430727482, 0.029228275641798973, -0.08208686113357544, -0.2068157196044922, -0.10113266110420227, -0.012165580876171589, 0.019549380987882614, -0.1829136312007904, -0.0608522891998291, 0.030775783583521843, 0.062093112617731094, -0.08521587401628494, -0.11082608252763748, 0.02578028477728367, -0.02587655931711197, -0.10601715743541718, 0.053491391241550446, 0.09228179603815079, 0.10462307184934616, -0.1544584035873413, 0.01970299333333969, -0.0025499225594103336, -0.12751349806785583, -0.14228053390979767, -0.09813544154167175, -0.1556943953037262, -0.15455684065818787, 0.04012012481689453, 0.006904925219714642, 0.014093044213950634, 0.1118047907948494, -0.011761174537241459, -0.0874086394906044, -0.06155821681022644, -0.048364732414484024, -0.0951564610004425, -0.030400441959500313, 0.015907635912299156, -0.03588278591632843, -0.11932012438774109, -0.014368465170264244, 0.012096185237169266, -0.03482381999492645, 0.003156089223921299, -0.0022054952569305897, -0.0885256752371788, -0.10210321098566055, 0.07173480093479156, 0.04820357263088226, 0.07537887990474701, 0.02680022455751896, -0.03766365721821785, 0.0029990801122039557, -0.17538517713546753, 0.07778222858905792, -0.02243117056787014, -0.07424947619438171, -0.12802354991436005, 0.15946932137012482, -0.014434004202485085, 0.11539101600646973, 0.15086381137371063, -0.044973958283662796, 0.09444278478622437, -0.08209580183029175, 0.07501164823770523, 0.056846145540475845, 0.038171395659446716, 0.05667714402079582, 0.08977752923965454, -0.051978886127471924, -0.053156327456235886, 0.08718428015708923, 0.03660134598612785, -0.11905664950609207, -0.057753145694732666, -0.05603650584816933, -0.0870383232831955, -0.003196804318577051, 0.01893061213195324, -0.0806002989411354, -0.08673574775457382, 0.05867399647831917, -0.042010046541690826, -1.021031380919965e-32, -0.019226159900426865, 0.05692790076136589, 0.06848026067018509, -0.02733929641544819, -0.04265248402953148, 0.04505668208003044, 0.04877433180809021, -0.07749626040458679, 0.08669799566268921, -0.060829728841781616, 0.10980228334665298, 0.22795119881629944, -0.07769384235143661, -0.04361214488744736, -0.07293564081192017, 0.05081072822213173, 0.06115477532148361, -0.10430265218019485, -0.026350127533078194, -0.09743466973304749, 0.04078466445207596, 0.12992633879184723, -0.10281770676374435, 0.16416554152965546, -0.10835277289152145, 0.14495517313480377, 0.09767958521842957, 0.04015698283910751, 0.02655625157058239, -0.05182713642716408, -0.10836488753557205, 0.05804409086704254, -0.14002487063407898, 0.06145092099905014, 0.02801181748509407, 0.055817000567913055, 0.1360175758600235, -0.28862014412879944, -0.09352870285511017, 0.014513656497001648, 0.07729806005954742, 0.05189044773578644, -0.06222148239612579, 0.007972720079123974, -0.015822747722268105, 0.05857822299003601, 0.08828772604465485, 0.16242627799510956, 0.19323696196079254, 0.04339515417814255, -0.07660108804702759, 0.19349458813667297, -0.01134707685559988, 0.11650396138429642, -0.004555083345621824, -0.06280901283025742, -0.065541572868824, -0.0823352262377739, -0.12949791550636292, 0.1408991664648056, -0.05155187100172043, 0.13166934251785278, -0.15487040579319, 0.04426826164126396, 0.007358399219810963, 0.20063847303390503, 0.015588776208460331, 0.027207767590880394, 0.030347341671586037, -0.045496128499507904, -0.016414739191532135, -0.05340525135397911, 0.03887450322508812, -0.17189690470695496, -0.0442323200404644, 0.14438728988170624, 0.10186239331960678, -0.16550274193286896, -0.13915526866912842, 0.14739251136779785, 0.1306248903274536, -0.08709699660539627, 0.11279426515102386, 0.012974963523447514, 0.09399699419736862, 0.18517151474952698, -0.006583237089216709, 0.028004728257656097, -0.162042036652565, -0.047352198511362076, -0.006804314907640219, -0.1301710158586502, -0.06492429971694946, 0.13239739835262299, 0.16006198525428772, -9.981746273979297e-08, 0.014933335594832897, -0.09326291084289551, 0.13204728066921234, -0.07526231557130814, 0.04748770594596863, -0.06145802140235901, -0.08977261185646057, 0.07834973931312561, -0.017533158883452415, 0.1334153562784195, -0.026762157678604126, 0.07533155381679535, -0.1325557678937912, -0.027400720864534378, -0.036237772554159164, 0.057599179446697235, -0.013659426011145115, 0.03984495624899864, -0.062480632215738297, 0.013894869945943356, -0.07066383212804794, 0.0034286838490515947, 0.1493818312883377, -0.0248127318918705, 0.005088024772703648, 0.09440410137176514, 0.00916628260165453, 0.06153235211968422, 0.04803325608372688, 0.020209316164255142, 0.017451416701078415, -0.08362184464931488, 0.12107305228710175, 0.1579091101884842, -0.06701318919658661, -0.005748838186264038, 0.07508127391338348, 0.07928752899169922, 0.03453166410326958, 0.16900219023227692, 0.12015650421380997, -0.011712986044585705, -0.07070361077785492, 0.07793908566236496, -0.07412116229534149, 0.013217546045780182, -0.17811310291290283, 0.04807208105921745, 0.05496187135577202, -0.17709727585315704, 0.05469275638461113, -0.07227384299039841, -0.009647121652960777, 0.10953710228204727, -0.03413718193769455, 0.1810947060585022, -0.120452381670475, 0.040374141186475754, 0.036304451525211334, 0.05033031105995178, 0.1780114471912384, -0.2133868783712387, -0.017933355644345284, 0.10990773886442184], "changes": {"1wk": 44.594590153635, "1mo": 5.675676633529707}}, {"text": "PREMIUM Cardiff Oncology Prices Oversubscribed $40 Million Stock Offering MT Newswires Tue, Dec 10, 2024, 3:51 PM Cardiff Oncology (CRDF) said Tuesday its oversubscribed public offering of nearly 15.4 million commo PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CRDF", "date": "2024-12-10T12:51:55+00:00", "sentiment": {"score": 0.03665055241435766, "confidence": 0.050951771438121796, "probabilities": {"positive": 0.050951771438121796, "negative": 0.014301219023764133, "neutral": 0.934747040271759}}, "embedding": [-0.07310402393341064, -0.11290591210126877, 0.03416506573557854, 0.07451310008764267, 0.12251342833042145, -0.07113175839185715, -0.12393047660589218, 0.16431936621665955, -0.0728544294834137, 0.12631195783615112, -0.023202167823910713, 0.018123555928468704, -0.03228679671883583, -0.03496361896395683, 0.027891404926776886, 0.01042031217366457, -0.045898519456386566, -0.16024307906627655, 0.09426356106996536, -0.018110500648617744, -0.22276544570922852, 0.1398874819278717, 0.07405600696802139, 0.2034197300672531, 0.10559642314910889, -0.14543676376342773, -0.2397003322839737, 0.1331639587879181, 0.005545197986066341, -0.017164530232548714, -0.014544718898832798, 0.023258447647094727, -0.016160957515239716, -0.013808988966047764, -0.017287977039813995, -0.07884994894266129, -0.07016701251268387, 0.019813144579529762, -0.2005486786365509, 0.17104436457157135, 0.23015710711479187, -0.06982091069221497, -0.18233884871006012, 0.05407796427607536, -0.05498248711228371, -0.1429034024477005, -0.0624547079205513, 0.017069010064005852, 0.0871679037809372, 0.27752840518951416, -0.059488583356142044, -0.18497374653816223, -0.10974670946598053, 0.03960033133625984, -0.0017685858765617013, -0.14352624118328094, -0.26188188791275024, 0.05465516448020935, -0.025186849758028984, -0.10874931514263153, 0.012310633435845375, -0.07924261689186096, -0.1899304986000061, 0.056766241788864136, 0.17556630074977875, 0.15460604429244995, 0.06289030611515045, 0.10692496597766876, 0.11058999598026276, -0.16570068895816803, 0.06281294673681259, 0.018765604123473167, 0.06406985968351364, 0.09531794488430023, -0.07205039262771606, 0.16220590472221375, 0.1890152543783188, -0.019446490332484245, 0.001916727633215487, -0.04378078132867813, 0.0504470057785511, -0.06085330620408058, 0.22651907801628113, -0.26079505681991577, 0.11203134059906006, -0.09418536722660065, 0.030594924464821815, 0.09271024167537689, 0.03471258282661438, -0.07046918570995331, 0.18664193153381348, -0.09167368710041046, -0.017101826146245003, 0.16053831577301025, -0.3432232737541199, 0.042558152228593826, -0.038661807775497437, -0.046619851142168045, -0.09013362228870392, 0.10580804198980331, 0.10438766330480576, 0.02471793070435524, -0.02805355004966259, 0.0010335544357076287, -0.06201047822833061, -0.1642199158668518, -0.009408644400537014, 0.12175639718770981, -0.11131828278303146, -0.00591072766110301, 0.021158888936042786, 0.16182614862918854, 0.06650976836681366, -0.2961270809173584, -0.10445697605609894, 0.2009468823671341, -0.142106831073761, 0.03905266150832176, -0.005016000475734472, -0.012149294838309288, -0.09397276490926743, 0.04717795178294182, -0.1333146095275879, -0.0952514186501503, -0.039530426263809204, -0.005505075678229332, -0.09221339970827103, 1.4125388110741497e-32, -0.06116073578596115, 0.18343545496463776, 0.16070492565631866, -0.060387592762708664, 0.06359013170003891, 0.07093751430511475, 0.13213509321212769, -6.342238339129835e-05, -0.23967275023460388, -0.1655428111553192, -0.16541337966918945, 0.2703606188297272, -0.054176077246665955, -0.1350327581167221, -0.1712198108434677, -0.33115771412849426, 0.0008422773098573089, 0.05349550023674965, 0.10946479439735413, 0.0025914243888109922, -0.02432837150990963, -0.19435830414295197, -0.17163215577602386, -0.08015231043100357, -0.08537465333938599, 0.02988334372639656, -0.018467577174305916, 0.21852503716945648, 0.1312280297279358, 0.13356514275074005, -0.2067393958568573, -0.0040810443460941315, 0.09431740641593933, -0.1292659342288971, -0.0502195805311203, -0.14388108253479004, -0.13746394217014313, -0.14624916017055511, 0.15440186858177185, -0.14738582074642181, 0.036271948367357254, -0.024611808359622955, -0.17016397416591644, 0.025329049676656723, -0.05875091254711151, 0.047067124396562576, -0.042166560888290405, -0.27501124143600464, 0.006473164074122906, -0.12167444825172424, -0.03768104687333107, 0.04059140011668205, -0.3380044400691986, 0.050551753491163254, -0.09424836188554764, -0.014992566779255867, 0.018775053322315216, -0.04848513379693031, 0.17862191796302795, 0.1054186299443245, 0.2622472941875458, 0.10126342624425888, 0.13725964725017548, -0.003899307455867529, -0.08242141455411911, 0.15485237538814545, -0.12221827358007431, -0.198663130402565, -0.07909316569566727, 0.1635333001613617, 0.049162857234478, 0.06034084036946297, 0.21427559852600098, -0.008135831914842129, -0.035288166254758835, -0.015785377472639084, 0.033785607665777206, -0.07363560050725937, 0.2143302857875824, 0.35981541872024536, 0.03560334071516991, -0.19715379178524017, -0.05097803473472595, 0.010621308349072933, 0.11477656662464142, -0.043490830808877945, -0.016039950773119926, -0.03812045231461525, 0.015715206041932106, 0.013198863714933395, 0.09417323023080826, -0.0778362900018692, -0.09349826723337173, -0.009080130606889725, 0.05219143256545067, -1.364342514132879e-32, -0.005538353696465492, 0.12332499027252197, -0.011339498683810234, -0.08160170912742615, -0.19932164251804352, 0.02623582072556019, -0.08623602986335754, 0.14324632287025452, 0.09503582864999771, 0.16121619939804077, 0.15803055465221405, 0.16769668459892273, -0.04581157863140106, 0.01819712109863758, 0.07319936156272888, -0.06082414090633392, 0.11841704696416855, -0.09062901884317398, 0.021607596427202225, -0.11395445466041565, -0.11728466302156448, 0.1676868498325348, -0.10597431659698486, 0.24399259686470032, 0.08474303036928177, 0.10677322745323181, 0.06431248784065247, 0.11604292690753937, 0.11755646020174026, 0.0024604275822639465, -0.11069782078266144, -0.15001226961612701, -0.16978642344474792, 0.10255321115255356, -0.02591121941804886, 0.051429349929094315, 0.32501694560050964, 0.1365811675786972, 0.056752096861600876, -0.04577678442001343, 0.07698234170675278, -0.06891192495822906, -0.15013276040554047, 0.011508879251778126, 0.0608605220913887, -0.0445372611284256, -0.042175982147455215, -0.07978209108114243, 0.3204943537712097, -0.057646483182907104, -0.05913892015814781, 0.23299703001976013, -0.02029457874596119, 0.10388697683811188, -0.13431665301322937, 0.03626604378223419, -0.17661389708518982, -0.015396996401250362, 0.007679998409003019, -0.04940079152584076, 0.05697684735059738, 0.0682913139462471, -0.3826824724674225, -0.1320553719997406, 0.08111517876386642, 0.1789395660161972, -0.02264377847313881, -0.020119009539484978, 0.09386048465967178, 0.019707754254341125, -0.05021973326802254, 0.00020208115165587515, 0.046042609959840775, -0.32226040959358215, -0.06424085050821304, 0.2713773846626282, 0.07891097664833069, 0.03037390671670437, -0.02872774377465248, 0.12233243137598038, 0.07999970763921738, -0.14489346742630005, 0.15555188059806824, -0.015968110412359238, -0.05474307760596275, -0.11691856384277344, 0.12519684433937073, -0.038595810532569885, -0.19959738850593567, -0.026512516662478447, 0.008690602146089077, -0.20478381216526031, -0.07084162533283234, 0.1276477873325348, 0.18270422518253326, -9.9304884315643e-08, 0.07266441732645035, -0.16432999074459076, 0.07327696681022644, -0.015848325565457344, 0.27985551953315735, -0.012845824472606182, -0.046309590339660645, 0.05918804183602333, 0.11070720106363297, 0.27834591269493103, -0.04534614458680153, -0.0660209208726883, 0.002739052753895521, 0.005869171116501093, -0.058943379670381546, 0.14039500057697296, -0.22053390741348267, 0.037738047540187836, -0.014827900566160679, 0.019700482487678528, 0.056661222130060196, 0.02787177823483944, 0.20480404794216156, 0.0350637286901474, 0.050806839019060135, 0.07207968831062317, 0.0038825313095003366, 0.15604408085346222, -0.04046362638473511, -0.02872529625892639, -0.02267049066722393, -0.13394685089588165, -0.126303032040596, 0.2825469672679901, -0.029358796775341034, -0.09332363307476044, 0.016882898285984993, 0.11410343647003174, -0.15687812864780426, 0.10956602543592453, 0.09052417427301407, -0.25801774859428406, 0.02028285339474678, 0.2033456265926361, 0.011835928075015545, 0.10968846827745438, -0.25451454520225525, 0.03299843147397041, 0.07329195737838745, -0.39310017228126526, 0.18170282244682312, 0.04367174580693245, 0.12460432946681976, 0.030806805938482285, -0.09266640990972519, 0.01241155806928873, -0.05287225544452667, 0.0933137834072113, -0.31000185012817383, 0.13805583119392395, 0.038447048515081406, -0.3739853501319885, 0.07418394088745117, 0.021781504154205322], "changes": {"1wk": 6.613762971184969, "1mo": 3.4391564927213896}}, {"text": "Cardiff Oncology price target raised to $10 from $7 at Piper Sandler TipRanks Sat, Dec 14, 2024, 2:50 PM 1 min read In This Article: CRDF -0.50% https://www.tipranks.com/news/the-fly/vertex-pharmaceuticals-price-target-raised-to-433-from-430-at-scotiabank Piper Sandler raised the firm\u2019s price target on Cardiff Oncology ( CRDF ) to $10 from $7 and keeps an Overweight rating on the shares. The company reported initial data from its ongoing randomized Phase II trial of onvansertib in RAS-mutated mutated metastatic colorectal cancer and the early randomized dataset seems to clearly support the hypothesis that onvansertib on top of chemotherapy provides meaningful clinical benefit, the analyst tells investors in a research note. Piper sees the data as meaningfully derisking.\u201d Pick the best stocks and maximize your portfolio: Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks! Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks Published first on TheFly \u2013 the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders\u2019 Hot Stocks on TipRanks >> Read More on CRDF: Unusually active option classes on open December 10th Cardiff Oncology prices $40M registered direct offering at $2.60 per share Cardiff Oncology Reports Promising Phase 2 Trial Results Cardiff Oncology\u2019s onvansertib shows efficacy in Phase 2 colorectal cancer trial Largest borrow rate increases among liquid names View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CRDF", "date": "2024-12-14T11:50:08+00:00", "sentiment": {"score": 0.7389588793739676, "confidence": 0.7504495978355408, "probabilities": {"positive": 0.7504495978355408, "negative": 0.011490718461573124, "neutral": 0.2380596101284027}}, "embedding": [-0.09078367054462433, -0.15013575553894043, -0.09129243344068527, 0.013953308574855328, 0.1397417038679123, -0.03137940540909767, 0.027053989470005035, 0.1835567206144333, 0.02599060721695423, 0.0509171187877655, -0.09960155189037323, 0.047605741769075394, -0.02195500209927559, 0.019843248650431633, -0.12809939682483673, 0.07803619652986526, 0.10280744731426239, -0.066449373960495, -0.11609557271003723, 0.03921447694301605, -0.2374018430709839, -0.09146685898303986, 0.18935038149356842, 0.10128995031118393, 0.05864610895514488, -0.16010606288909912, -0.05507107079029083, 0.06669960916042328, -0.12815558910369873, -0.01664889045059681, 0.05542264133691788, 0.1239059641957283, -8.418325160164386e-05, -0.07069781422615051, -0.09939585626125336, -0.0958814024925232, -0.05579124763607979, 0.15572208166122437, -0.03305729106068611, 0.10522127896547318, 0.05042783543467522, -0.03869395703077316, -0.22729335725307465, 0.038081493228673935, -0.028783323243260384, -0.17725086212158203, 0.03600018098950386, 0.03502669185400009, 0.05090542510151863, 0.19900450110435486, -0.28150102496147156, -0.09454571455717087, -0.05658826231956482, 0.06665290147066116, -0.07778991758823395, -0.023505641147494316, -0.14935080707073212, -0.02780613675713539, 0.08345407992601395, -0.04853345453739166, -0.02469227835536003, -0.039787277579307556, 0.06560688465833664, 0.020350689068436623, 0.18453764915466309, 0.059042174369096756, -0.06555988639593124, -0.004197394475340843, -0.023493288084864616, -0.03370538726449013, 0.1573186218738556, -0.07146604359149933, 0.027194896712899208, 0.04850688949227333, -0.053692594170570374, 0.09656650573015213, 0.11376394331455231, 0.06784137338399887, 0.10335798561573029, 0.03956885635852814, -0.012787187471985817, -0.10285481065511703, 0.1185363233089447, -0.020695760846138, 0.024747315794229507, -0.12248021364212036, 0.08964809030294418, 0.10315820574760437, 0.09125416725873947, 0.009741732850670815, 0.1778431534767151, 0.004659983329474926, -0.018684085458517075, 0.047776058316230774, -0.034441929310560226, -0.00995638594031334, -0.07051443308591843, -0.05521208420395851, 0.013953950256109238, 0.016646049916744232, 0.051667630672454834, -0.00338456267490983, -0.12080832570791245, -0.0598142109811306, -0.04122620075941086, -0.14428676664829254, 0.0381225124001503, -0.0226484052836895, 0.045144617557525635, -0.007931436412036419, 0.0044209579937160015, 0.16586662828922272, -0.05556982383131981, -0.03911244869232178, -0.12897998094558716, 0.17494367063045502, -0.049826886504888535, -0.029653627425432205, 0.10522091388702393, 0.04296083375811577, -0.06414417922496796, 0.02786153554916382, -0.0717926099896431, -0.06588144600391388, -0.009818356484174728, 0.14358210563659668, -0.2373584806919098, 1.4011826540244433e-32, -0.003905142191797495, 0.02550582028925419, 0.10860844701528549, -0.09637761861085892, -0.08410051465034485, -0.018286971375346184, 0.04576176777482033, -0.037197042256593704, -0.18815144896507263, -0.0985853374004364, -0.09366109222173691, -0.002114244969561696, 0.028348498046398163, -0.005784962791949511, -0.1286805421113968, -0.14414924383163452, -0.026051053777337074, -0.014865468256175518, -0.15581606328487396, -0.06436502933502197, 0.01508556678891182, -0.007017964497208595, -0.126885786652565, -0.12703289091587067, -0.014347118325531483, -0.020386910066008568, -0.11539053171873093, 0.06581477075815201, 0.08175280690193176, 0.1010085865855217, -0.10814692825078964, -0.028817199170589447, -0.01847723126411438, -0.10505515336990356, -0.13235054910182953, -0.06850023567676544, -0.13864535093307495, -0.1161169782280922, 0.023987794294953346, 0.0464644581079483, -0.02190452814102173, 0.1390659213066101, 0.02837526611983776, -0.03608597069978714, -0.01345939002931118, -0.030052555724978447, -0.1961003690958023, -0.0322255864739418, -0.026729615405201912, -0.03942510485649109, -0.13364779949188232, -0.04366246983408928, 0.05447190999984741, 0.050636302679777145, -0.06558657437562943, 0.012712341733276844, -0.06127743795514107, -0.08462143689393997, 0.001732723438180983, 0.1118464544415474, 0.024755550548434258, 0.024343162775039673, -0.03667687252163887, -0.010247668251395226, -0.14528417587280273, 0.1556369513273239, -0.05107622966170311, -0.059800054877996445, -0.1171773374080658, 0.1430104672908783, 0.02250158227980137, 0.1273586004972458, 0.2548031806945801, -0.020615752786397934, 0.04876085743308067, -0.06572183221578598, 0.07415212690830231, 0.013489295728504658, 0.0663527175784111, 0.11111269891262054, 0.045676082372665405, -0.08852337300777435, -0.04963091015815735, 0.0663471668958664, -0.005518358200788498, -0.09978403151035309, -0.052846092730760574, -0.04953900724649429, -0.09984804689884186, 0.02419145405292511, 0.09731253236532211, -0.06955669820308685, -0.09368140250444412, 0.023534810170531273, 0.003905253252014518, -1.2151747789390262e-32, -0.13394427299499512, 0.10788243263959885, 0.039490677416324615, 0.0244572926312685, -0.02661045826971531, 0.03155107796192169, 0.08526045829057693, -0.13432928919792175, 0.057063303887844086, -0.035221897065639496, 0.03153511509299278, 0.1645965427160263, -0.057148195803165436, -0.026264749467372894, -0.09186403453350067, 0.026534980162978172, 0.03423357382416725, -0.05498658865690231, -0.002081071026623249, -0.11576423048973083, -0.0035584131255745888, 0.1631390005350113, -0.08433280140161514, 0.19221432507038116, -0.07657827436923981, 0.12261205166578293, 0.11300484836101532, 0.13655875623226166, 0.03756580501794815, 0.006995913106948137, -0.13738642632961273, 0.0747891515493393, -0.13831138610839844, 0.08981867879629135, -0.059853438287973404, 0.0837581530213356, 0.09558641910552979, -0.24880486726760864, -0.05556589737534523, 0.031867384910583496, 0.07354221493005753, 0.012078926898539066, -0.09010569006204605, 0.015047398395836353, 0.04106568545103073, 0.1034880056977272, 0.012649400159716606, 0.1212310791015625, 0.23225528001785278, -8.77183920238167e-05, -0.032312002032995224, 0.11856047064065933, 0.0036741956137120724, 0.21754257380962372, -0.027567213401198387, -0.04819031432271004, 0.025940537452697754, -0.0043645319528877735, -0.15517199039459229, 0.06057196110486984, -0.045581329613924026, 0.17766283452510834, -0.13554689288139343, 0.02877391315996647, -0.0324166901409626, 0.14398875832557678, -0.01008804515004158, -0.015821607783436775, 0.09351927787065506, -0.15764427185058594, -0.04514569416642189, -0.12402608245611191, 0.18188779056072235, -0.09825163334608078, -0.052155572921037674, 0.17190681397914886, 0.08539818972349167, -0.08290457725524902, -0.11754929274320602, 0.11563155800104141, 0.027180533856153488, -0.1329304724931717, 0.06332637369632721, 0.007113419007509947, 0.05434894934296608, 0.1449050009250641, -0.022922582924365997, -0.0474710613489151, -0.10177332907915115, -0.05877158045768738, -0.03815659508109093, -0.14263693988323212, -0.08210373669862747, 0.0732266902923584, 0.0465945228934288, -9.987925153609467e-08, 0.05386859178543091, -0.15184877812862396, 0.06506408005952835, 0.022175993770360947, 0.11132325977087021, -0.025710543617606163, -0.032781925052404404, 0.12421885877847672, 0.014540301635861397, 0.17346420884132385, 0.07121212035417557, 0.08415184170007706, -0.141109436750412, -0.0495208241045475, -0.03366092965006828, 0.022113705053925514, -0.03438291326165199, 0.002941030776128173, -0.035066958516836166, 0.006738749798387289, -0.06672244518995285, 0.10811223834753036, 0.07416267693042755, 0.003430454758927226, 0.0265401229262352, 0.045544642955064774, 0.0010601365938782692, 0.09789273142814636, 0.07974755018949509, 0.07764548808336258, -0.017993636429309845, -0.08114549517631531, 0.12295865267515182, 0.14064006507396698, 0.02628447860479355, 0.004283417481929064, 0.0438685342669487, 0.1066201850771904, 0.027489181607961655, 0.19447579979896545, 0.05816354975104332, -0.06775826215744019, -0.13044919073581696, 0.014690447598695755, 0.00945963803678751, 0.0306695606559515, -0.21719983220100403, 0.0818314328789711, 0.11074107140302658, -0.20900708436965942, 0.1405612826347351, -0.008764860220253468, 0.03230895847082138, 0.08866173774003983, 0.007940344512462616, 0.1395714432001114, -0.19784851372241974, 0.022379375994205475, -0.07099949568510056, 0.042066652327775955, 0.16854234039783478, -0.27312153577804565, -0.06591850519180298, 0.1440812051296234], "changes": {"1wk": 5.707196205938267, "1mo": -10.421843494953514}}, {"text": "Cardiff Oncology Prices Oversubscribed $40 Million Underwritten Registered Direct Offering Cardiff Oncology, Inc. Tue, Dec 10, 2024, 3:20 PM 5 min read In This Article: CRDF -0.50% Cardiff Oncology, Inc. SAN DIEGO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF) (\u201cCardiff Oncology\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced the pricing of an underwritten offering of 15,384,619 shares of its common stock at an offering price of $2.60 per share, before deducting underwriting discounts and commissions. All of the shares of common stock are being offered by the Company. The financing included participation from new mutual fund and healthcare dedicated investors, along with support from existing investors. The gross proceeds to the Company, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $40 million. The offering is expected to close on or about December 11, 2024, subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds from this offering to fund clinical costs for onvansertib in first-line RAS-mutated metastatic colorectal cancer (mCRC) and for working capital and other general corporate purposes. TD Cowen is acting as lead book-runner for the offering. William Blair is also acting as book-runner, H.C. Wainwright & Co. is acting as lead manager, and Craig-Hallum is acting as co-manager for the offering. The offering is being made pursuant to a shelf registration statement on Form S-3 previously filed with the U.S. Securities and Exchange Commission (\u201cSEC\u201d) and declared effective by the SEC on April 25, 2022. A prospectus supplement and accompanying prospectus relating to and describing the terms of the offering will be filed with the SEC. Copies of the prospectus supplement and the accompanying prospectus, may be obtained, when available, by contacting TD Securities (USA) LLC, 1 Vanderbilt Ave., New York, NY 10017, by telephone at (855) 495-9846, or by email at TD.ECM_Prospectus@tdsecurities.com . This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction. About Cardiff Oncology, Inc. Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers. The Company's lead asset is onvansertib, a PLK1 inhibitor being evaluated in combination with standard-of-care (SoC) therapeutics in clinical programs targeting indications such as RAS-mutated metastatic colorectal cancer (mCRC) and metastatic pancreatic ductal adenocarcinoma (mPDAC), as well as in investigator-initiated trials in small cell lung cancer (SCLC) and triple negative breast cancer (TNBC). These programs and the Company's broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SoC alone. Story Continues Forward-Looking Statements Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of words such as \"anticipate,\" \"believe,\" \"forecast,\" \"estimated\" and \"intend\" or other similar terms or expressions that concern the Company\u2019s expectations, strategy, plans or intentions. These forward-looking statements are based on the Company\u2019s current expectations and actual results could differ materially. Forward-looking statements include statements regarding the closing of the offering of common stock; and the Company\u2019s intended use of proceeds. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, the satisfaction of customary closing conditions related to the offering, our need for additional financing; clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; the Company\u2019s clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of the Company\u2019s product candidate; uncertainties of government or third party payer reimbursement; dependence on key personnel; limited experience in marketing and sales; substantial competition; uncertainties of patent protection and litigation; dependence upon third parties; and risks related to failure to obtain U.S. Food and Drug Administration (\u201cFDA\u201d) clearances or approvals and noncompliance with FDA regulations. There are no guarantees that the Company\u2019s product candidate will be utilized or prove to be commercially successful. Additionally, there are no guarantees that future clinical trials will be completed or successful or that any precision medicine therapeutics will receive regulatory approval for any indication or prove to be commercially successful. Investors should read the risk factors set forth in\u00a0the Company\u2019s Annual Report on Form 10-K for the year ended\u00a0December 31, 2023, and other periodic reports filed with the\u00a0SEC. While the list of factors presented here is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Forward-looking statements included herein are made as of the date hereof, and\u00a0the Company does not undertake any obligation to update publicly such statements to reflect subsequent events or circumstances. Cardiff Oncology Contact: James Levine Chief Financial Officer 858-952-7670 jlevine@cardiffoncology.com Investor Contact: Kiki Patel, PharmD Gilmartin Group 332-895-3225 Kiki@gilmartinir.com Media Contact: Grace Spencer Taft Communications 609-583-1151 grace@taftcommunications.com View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CRDF", "date": "2024-12-10T12:20:00+00:00", "sentiment": {"score": 0.00891619548201561, "confidence": 0.026513652876019478, "probabilities": {"positive": 0.026513652876019478, "negative": 0.017597457394003868, "neutral": 0.9558889269828796}}, "embedding": [-0.08374324440956116, -0.11184342205524445, -0.0704100951552391, -0.023126695305109024, -0.037829600274562836, -0.027284517884254456, 0.046602148562669754, 0.14017337560653687, 0.13360053300857544, 0.10121385753154755, -0.012630125507712364, -0.03784375637769699, -0.01110796444118023, -0.03266550973057747, -0.13070429861545563, 0.04479198530316353, -0.057327888906002045, -0.003030344843864441, -0.12739120423793793, 0.12451906502246857, -0.06454838067293167, 0.0028834729455411434, 0.008866981603205204, 0.05990864336490631, -0.014042826369404793, -0.14067406952381134, -0.00209277612157166, 0.05926916375756264, -0.18185676634311676, -0.03958579897880554, 0.10296066105365753, 0.02256692945957184, 0.040185414254665375, -0.0412442609667778, 0.033217914402484894, 0.03535705432295799, -0.1396545171737671, 0.08884723484516144, -0.08759153634309769, 0.11167468130588531, -0.02557104080915451, -0.03671662509441376, -0.17763209342956543, 0.09546148777008057, 0.029556773602962494, -0.111834317445755, -0.11548183858394623, 0.028743619099259377, 0.020640071481466293, 0.11534740775823593, -0.1161976307630539, -0.0413360670208931, -0.09541614353656769, 0.05984391272068024, -0.04312634468078613, -0.009643446654081345, -0.16047051548957825, 0.038099974393844604, 0.017162080854177475, -0.05322914570569992, -0.005489327013492584, -0.02347799763083458, -0.02952812798321247, 0.0361684113740921, 0.19145460426807404, 0.04081946238875389, -0.0041270144283771515, 0.009441067464649677, -0.0406879186630249, -0.02448136731982231, 0.16427995264530182, -0.09367373585700989, -0.04750721901655197, -1.5329569578170776e-05, -0.14952152967453003, 0.07316301763057709, 0.1410219520330429, 0.09995739161968231, 0.10661521553993225, -0.1235194057226181, 0.07007543742656708, 0.06468196213245392, 0.08484560996294022, -0.08600878715515137, -0.018819794058799744, 0.014888457022607327, 0.05526583641767502, 0.13945558667182922, 0.09945299476385117, 0.045150723308324814, 0.08343324810266495, -0.04869354888796806, -0.03928167000412941, 0.006312105804681778, -0.10165101289749146, -0.008777178823947906, -0.007583802565932274, -0.015287874266505241, 0.017717638984322548, 0.09587651491165161, 0.03875315189361572, -0.023644190281629562, -0.09649930894374847, -0.10730260610580444, -0.09714218974113464, -0.1284428834915161, 0.04263490065932274, -0.04550228267908096, 0.032008081674575806, 0.007418385241180658, -0.09392523020505905, 0.09394130855798721, -0.10350678861141205, -0.017803901806473732, -0.06779986619949341, 0.15104037523269653, 0.00677830632776022, -0.015701984986662865, 0.16696590185165405, -0.049882322549819946, 0.025730255991220474, 0.07072291523218155, -0.06418498605489731, -0.07804335653781891, -0.09647302329540253, -0.05026077851653099, -0.09996567666530609, 7.169954241463436e-33, -0.08876540511846542, -0.03539658710360527, 0.0683731809258461, -0.07508701831102371, -0.023358622565865517, -0.029592355713248253, 0.11597168445587158, 0.047069892287254333, -0.16392821073532104, -0.0654088482260704, -0.13070359826087952, 0.038759831339120865, -0.011228475719690323, -0.13306090235710144, -0.13044552505016327, -0.07990678399801254, 0.03847513347864151, 0.04138052463531494, -0.030490268021821976, -0.02385125495493412, 0.0009817127138376236, 0.06915786117315292, -0.09083007276058197, 0.016534963622689247, -0.07417361438274384, -0.07290801405906677, -0.11344894766807556, 0.05093520134687424, 0.10378003120422363, 0.06556648015975952, -0.07791447639465332, -0.01253579556941986, 0.02225160039961338, -0.08986185491085052, -0.07662953436374664, -0.0783597007393837, -0.1602206528186798, -0.08500370383262634, 0.11201499402523041, 0.046794064342975616, -0.10552296042442322, 0.0864681527018547, -0.056589022278785706, -0.0714532732963562, -0.05592084676027298, -0.007009146735072136, 0.049911268055438995, 0.02567349560558796, -0.01472050603479147, 0.013033424504101276, -0.09936640411615372, -0.03081831894814968, -0.014411697164177895, -0.0010313941165804863, -0.012695388868451118, -0.07424931973218918, -0.059026531875133514, -0.0023551825433969498, 0.06444580852985382, 0.12238200008869171, 0.08526232838630676, 0.11172233521938324, -0.07096904516220093, 0.06775885075330734, -0.15452630817890167, 0.09627747535705566, -0.06975923478603363, -0.05727088823914528, -0.04736567661166191, 0.027032891288399696, -0.11097609251737595, 0.056374114006757736, 0.1740453839302063, -0.052758581936359406, 0.04427823796868324, -0.04661433771252632, 0.07832393795251846, 0.09435566514730453, 0.05061192065477371, 0.1231147050857544, -0.01573321409523487, -0.024954015389084816, -0.09249809384346008, 0.02526457980275154, -0.04968313127756119, -0.032613251358270645, -0.025592463091015816, -0.050981082022190094, -0.02616230957210064, 0.02115452289581299, 0.11413756757974625, -0.12226022034883499, -0.1519443541765213, 0.06207519769668579, 0.12282714247703552, -6.882297549505776e-33, -0.03941347822546959, 0.006403328850865364, 0.018982689827680588, -0.05415922403335571, -0.016481777653098106, 0.09217371791601181, 0.049447908997535706, -0.12078231573104858, 0.02063155546784401, -0.01569710671901703, -0.0797705426812172, 0.10107288509607315, -0.01693703979253769, -0.004454213660210371, -0.0374334380030632, 0.0238893274217844, 0.022667666897177696, 0.0039345575496554375, -0.018589956685900688, -0.034082986414432526, -0.03176533803343773, 0.2569296658039093, -0.011149659752845764, 0.0387144535779953, -0.04188132658600807, 0.11893969774246216, 0.05811809003353119, 0.14164896309375763, 0.05029930919408798, 0.02193920500576496, -0.03587300330400467, -0.04152815416455269, -0.21560923755168915, 0.0454675629734993, -0.08091559261083603, -0.04608306288719177, 0.12236738204956055, -0.05322740972042084, 0.018843162804841995, -0.000864492729306221, 0.09595886617898941, -0.03346656262874603, 0.09342226386070251, 0.06415773928165436, 0.08979614078998566, -0.0031860615126788616, 0.06477943807840347, -0.07160322368144989, 0.1813211292028427, -0.00949099287390709, -0.062423042953014374, 0.08174998313188553, -0.023716941475868225, 0.07598721235990524, -0.08593027293682098, 0.021056348457932472, -0.004326623398810625, -0.06726491451263428, -0.002778966212645173, -0.018814029172062874, 0.08161090314388275, 0.09413391351699829, -0.0244747344404459, 0.0345754474401474, 0.0943932756781578, 0.10286876559257507, 0.013341301120817661, 0.028309322893619537, 0.05970710515975952, -0.08250361680984497, -0.08243877440690994, -0.10249999165534973, 0.045736510306596756, -0.17851173877716064, -0.015618320554494858, 0.12386184930801392, 0.05181172490119934, -0.1488131284713745, -0.06529843807220459, 0.050236064940690994, -0.010551436804234982, -0.02132588066160679, 0.05657082051038742, 0.04485157132148743, 0.03503083437681198, 0.035790469497442245, 0.03630013018846512, 0.047587983310222626, -0.1356549859046936, 0.0029601771384477615, 0.015379432588815689, -0.04853685945272446, 0.07771991193294525, 0.16726386547088623, 0.029827933758497238, -9.967641290131724e-08, 0.04552479088306427, -0.10651993751525879, 0.07318275421857834, -0.05755264684557915, 0.1705525815486908, -0.04283609241247177, 0.033267196267843246, 0.054871395230293274, 0.07613460719585419, 0.17864134907722473, 0.07961823046207428, 0.12331940233707428, -0.10389568656682968, 0.007398056797683239, -0.1623699963092804, 0.04675522446632385, -0.1318207085132599, 0.00500638410449028, -0.05042916536331177, 0.03938882052898407, -0.012664075009524822, 0.008481873199343681, 0.01634283736348152, 0.011732256039977074, 0.041763052344322205, -0.02764512412250042, 0.021250203251838684, 0.10811793059110641, -0.008350109681487083, 0.025087274610996246, 0.031488679349422455, 0.026096787303686142, 0.0635295882821083, 0.1345394253730774, -0.023094961419701576, -0.06699836254119873, 0.04213106632232666, 0.1847548931837082, -0.00799567624926567, 0.18969416618347168, 0.02549673430621624, -0.044470492750406265, 0.026960300281643867, 0.11295972019433975, 0.07458020001649857, -0.004015910904854536, -0.21665894985198975, 0.02781885303556919, 0.08741393685340881, -0.2521025538444519, 0.026521388441324234, 0.013264583423733711, -0.017968468368053436, 0.048932015895843506, -0.01721198856830597, 0.057173486799001694, -0.0719902366399765, 0.03852728009223938, -0.07567383348941803, 0.028544673696160316, 0.03856902942061424, -0.2938586473464966, 0.06989116221666336, 0.11049620807170868], "changes": {"1wk": 6.613762971184969, "1mo": 3.4391564927213896}}, {"text": "What's Going On With Cardiff Oncology Stock On Tuesday? Vandana Singh Tue, Dec 10, 2024, 6:16 PM 2 min read What's Going On With Cardiff Oncology Stock On Tuesday? On Tuesday, Cardiff Oncology, Inc. (NASDAQ: CRDF ) revealed initial data from the CRDF-004 Phase 2 trial, which evaluates onvansertib in combination with standard-of-care (SoC) in patients with first-line RAS-mutated metastatic colorectal cancer (mCRC) . The CRDF-004 phase 2 trial is currently enrolling patients with mCRC who have a documented KRAS or NRAS mutation . Onvansertib is added to SoC consisting of FOLFIRI plus bevacizumab or FOLFOX plus bevacizumab. Patients are being randomized in a 1:1:1 ratio to either 20mg of onvansertib plus SoC, 30mg of onvansertib plus SoC, or SoC alone. Efficacy and safety data are for all evaluable patients as of November 26. An objective response rate of 57% was observed in all onvansertib patients, with 50% in the 20mg dose of onvansertib + SoC arm and 64% in the 30mg dose of onvansertib + SoC arm, compared to 33% in the SoC alone arm. Spider Plots, displaying the change in tumor size from baseline for each patient over time, demonstrate deeper responses observed in patients receiving the 30mg dose of onvansertib combined with the SoC compared to the control arms and 20mg dose of onvansertib arms. Onvansertib, in combination with chemo/bevacizumab, was well-tolerated, and no major or unexpected toxicities were observed. Additional clinical data from the CRDF-004 trial is expected in 1H 2025. \"We are highly encouraged by the robust efficacy signal and favorable safety profile observed with onvansertib plus standard-of-care from the first 30 evaluable patients in our randomized first-line RAS-mutated mCRC CRDF-004 trial,\" said Fairooz Kabbinavar, MD, FACP, Chief Medical Officer of Cardiff Oncology. \"Our data shows an objective response rate of 64% in patients receiving the 30 mg dose of onvansertib in combination with standard of care, significantly higher than the 33% objective response rate observed in the control arms of standard of care alone. In addition, as can be seen in the spider plots, we are observing deeper tumor response in patients receiving the 30mg dose of onvansertib compared to those receiving the 20mg dose with similar safety profiles for both doses.\" Price Action: CRDF stock was trading 52% higher to $3.71 at the last check on Tuesday. Read Next: Rocket Lab Achieves Milestone In Hypersonic Testing for DoD's MACH-TB Project Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? Story Continues This article What's Going On With Cardiff Oncology Stock On Tuesday? originally appeared on Benzinga.com \u00a9 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CRDF", "date": "2024-12-10T15:16:17+00:00", "sentiment": {"score": 0.37146734073758125, "confidence": 0.3927009105682373, "probabilities": {"positive": 0.3927009105682373, "negative": 0.02123356983065605, "neutral": 0.5860655307769775}}, "embedding": [-0.009696700610220432, -0.1206928938627243, -0.0873367041349411, -0.08697157353162766, -0.01517174020409584, -0.10353820025920868, -0.10619815438985825, 0.1991555541753769, 0.0600891187787056, -0.0067491475492715836, -0.06237007677555084, 0.033028773963451385, 0.08432266116142273, 0.001875043846666813, -0.1008693054318428, 0.10342013090848923, 0.06706348061561584, -0.037442997097969055, -0.12783101201057434, 0.05158431828022003, -0.13374729454517365, -0.06815776228904724, 0.09610171616077423, 0.06569183617830276, -0.09129811823368073, -0.05494996905326843, -0.07174219191074371, 0.01689981482923031, -0.0885569378733635, 0.004280759487301111, 0.07855464518070221, 0.1093020960688591, -0.017025025561451912, -0.04971006512641907, -0.059206150472164154, -0.06104189157485962, -0.15557803213596344, 0.16953596472740173, -0.15461993217468262, 0.016511093825101852, -0.09893880784511566, -0.03907458484172821, -0.10845616459846497, 0.016348328441381454, -0.022593235597014427, -0.2120307981967926, -0.09497412294149399, -0.04250388219952583, 0.01695513166487217, 0.2314930558204651, -0.09214792400598526, -0.06393304467201233, -0.14675799012184143, 0.2359286993741989, 0.04774996638298035, -0.11867731809616089, -0.1920200139284134, 0.033165186643600464, 0.05809108540415764, 0.02315697818994522, 0.015348517335951328, -0.12346924096345901, -0.021444078534841537, 0.03976070135831833, 0.11134959012269974, 0.1047590970993042, 0.007572010159492493, -0.14807182550430298, 0.04337433725595474, -0.07760748267173767, 0.07636363059282303, -0.024733103811740875, 0.06299085170030594, 0.1333097368478775, -0.04087463766336441, 0.07175534963607788, 0.14957073330879211, 0.09643355011940002, 0.06249985843896866, -0.07664795964956284, 0.003000278025865555, 0.14398439228534698, 0.14195433259010315, -0.04777635633945465, 0.07552766799926758, 0.015530124306678772, -0.016244173049926758, 0.16042299568653107, 0.08790889382362366, 0.0027530957013368607, 0.24992559850215912, 0.1656586229801178, 0.001208208967000246, -0.05601060017943382, 0.04145850986242294, -0.034300558269023895, -0.05315593630075455, -0.0019674329087138176, 0.021988309919834137, 0.021139830350875854, -0.008490853011608124, -0.049426037818193436, -0.11117322742938995, -0.015476461499929428, -0.12832856178283691, -0.049394384026527405, 0.002244797069579363, -0.06601814180612564, -0.1293405443429947, 0.024887690320611, 0.09519451856613159, 0.05266617611050606, 0.04459771513938904, -0.025328775867819786, -0.07678613066673279, 0.18568825721740723, -0.006499068811535835, -0.024849247187376022, 0.09876077622175217, -0.028778307139873505, -0.009654304943978786, 0.0162435881793499, 0.008433052338659763, -0.10444547235965729, 0.09614485502243042, 0.17037856578826904, -0.03515518456697464, 1.741648576629589e-32, -0.006702545564621687, 0.03570327162742615, 0.08285602927207947, 0.04690900072455406, 0.03729721158742905, -0.01830170676112175, 0.08650772273540497, -0.032378409057855606, -0.07660682499408722, -0.1448047161102295, -0.0046312203630805016, -0.03150762990117073, 0.10443612933158875, -0.0714525356888771, -0.14891162514686584, -0.08671834319829941, 0.05912181735038757, -0.04632243886590004, -0.12995301187038422, 0.004982468672096729, 0.06662587076425552, 0.05263454467058182, -0.045060887932777405, -0.04686674103140831, -0.03754277527332306, 0.03136561065912247, -0.0384991355240345, 0.1693747192621231, 0.03698878735303879, 0.03668925538659096, -0.11242178082466125, -0.03895530104637146, 0.015953071415424347, -0.04354251176118851, -0.17876413464546204, -0.06602522730827332, -0.050676893442869186, -0.07382408529520035, -0.00936167873442173, 0.046504050493240356, 0.0022429432719945908, 0.045818716287612915, -0.1304069608449936, -0.030218224972486496, 0.05638260394334793, -0.18815302848815918, -0.10575542598962784, -0.0989227220416069, -0.022410770878195763, 0.05895417556166649, -0.10346958041191101, -0.028400514274835587, -0.024192504584789276, 0.04119538888335228, -0.06842873245477676, 0.06191844493150711, -0.04211709648370743, 0.007439218461513519, 0.0973874181509018, 0.08120492845773697, 0.012207859195768833, -0.009420960210263729, 0.04486013203859329, 0.021995970979332924, 0.05332550033926964, 0.008873412385582924, -0.12710991501808167, -0.14574778079986572, -0.15474200248718262, 0.025173980742692947, -0.06917659193277359, 0.03892071545124054, 0.1605508029460907, 0.029298193752765656, 0.057796262204647064, -0.05820612609386444, 0.030708393082022667, 0.12244528532028198, -0.10024051368236542, 0.12873947620391846, -0.15398424863815308, -0.019575944170355797, -0.1207975521683693, 0.15511354804039001, -0.0544859878718853, -0.1606590449810028, 0.004568982869386673, -0.02607239969074726, -0.15015152096748352, 0.005084088537842035, 0.1516328901052475, -0.10722601413726807, -0.08315425366163254, 0.041843827813863754, 0.11645817756652832, -1.8097462868038687e-32, -0.04615138843655586, 0.12070964276790619, 0.028720099478960037, -0.043735504150390625, -0.08176928758621216, 0.10983845591545105, 0.10292163491249084, -0.05782030522823334, 0.027752332389354706, -0.14393481612205505, 0.10120873153209686, 0.17190143465995789, -0.11524944752454758, -0.13283708691596985, -0.14619885385036469, 0.06638388335704803, 0.0334654338657856, 0.03669760748744011, -0.059865839779376984, 0.04692543298006058, 0.03772147744894028, 0.17843474447727203, 0.05097128450870514, 0.03528469800949097, -0.0930398628115654, 0.09468762576580048, 0.1709294617176056, 0.08010540902614594, 0.08921220153570175, -0.02507786639034748, 0.003702650312334299, 0.03301805630326271, -0.19058537483215332, -0.016834283247590065, 0.0018129716627299786, -0.0187211986631155, 0.061943113803863525, -0.15194451808929443, -0.0630972757935524, -0.005542402621358633, 0.03956499695777893, 0.08121130615472794, -0.07884548604488373, 0.036367204040288925, -0.0236152783036232, -0.0029539091046899557, 0.04279864579439163, 0.03677447885274887, 0.14877089858055115, -0.16333052515983582, -0.04568742215633392, 0.1242358386516571, -0.03307010978460312, 0.07080841064453125, 0.10397599637508392, -0.06369766592979431, 0.07499158382415771, -0.05564756691455841, -0.12901821732521057, 0.10276424884796143, -0.034036941826343536, 0.037509262561798096, -0.07098273932933807, -0.08059905469417572, 0.13130536675453186, 0.2279818058013916, -0.05434263497591019, -0.016365835443139076, 0.17395205795764923, -0.08055049926042557, -0.09582073986530304, -0.10177548229694366, -0.03333386406302452, -0.09202294051647186, -0.019092077389359474, 0.03656994551420212, 0.11565632373094559, -0.08115200698375702, -0.06351672857999802, 0.03924961015582085, -0.049021538347005844, -0.15472957491874695, 0.008580491878092289, -0.020032556727528572, 0.0024528640788048506, 0.05097535625100136, -0.07166746258735657, -0.01832628808915615, 0.05489252880215645, -0.03730738162994385, -0.02433015964925289, -0.062765933573246, -0.07617484778165817, 0.10632166266441345, 0.0664014145731926, -1.0128295002687082e-07, 0.05528877303004265, -0.12959825992584229, 0.03263507038354874, -0.05748923122882843, 0.06741519272327423, -0.02972768247127533, -0.06508485972881317, 0.014337792992591858, -0.08342530578374863, 0.15334764122962952, 0.08962401747703552, 0.11343980580568314, -0.05730847269296646, -0.028282184153795242, -0.005794812925159931, 0.02857014909386635, 0.002966932486742735, 0.005395613610744476, -0.04870811104774475, 0.06520114839076996, -0.10817613452672958, -0.12612946331501007, 0.010614844039082527, -0.06395496428012848, 0.02446284331381321, 0.010893472470343113, 0.05492057278752327, 0.0642770379781723, -0.0010348116047680378, -0.016224801540374756, 0.00571131706237793, -0.0927908718585968, 0.04603908210992813, 0.09315524995326996, -0.040730349719524384, -0.06613197922706604, 0.06078149378299713, 0.09746389091014862, 0.08126755058765411, 0.1953020542860031, 0.13192610442638397, -0.0387803390622139, -0.08682906627655029, 0.04783337190747261, -0.05490179732441902, 0.057076118886470795, -0.18039116263389587, -0.004452995490282774, 0.030612077564001083, -0.1865045428276062, -0.059102147817611694, -0.0036020283587276936, -0.0236225388944149, -0.018963802605867386, -0.086934894323349, 0.05897261202335358, -0.05605695769190788, 0.0716494545340538, 0.09443884342908859, -0.011972101405262947, 0.03921182081103325, -0.08693055808544159, -0.017249224707484245, -0.03116569109261036], "changes": {"1wk": 41.534390082695296, "1mo": 3.4391564927213896}}, {"text": "PREMIUM Update: Cardiff Oncology Shares Surge After Report of High Tumor Response in Mid-Stage Onvansertib Trial MT Newswires Tue, Dec 10, 2024, 7:50 PM 1 min read (Updates with stock price movement in the headline and first paragraph.) Cardiff Oncology (CRDF) PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CRDF", "date": "2024-12-10T16:50:04+00:00", "sentiment": {"score": 0.06001301947981119, "confidence": 0.07193480432033539, "probabilities": {"positive": 0.07193480432033539, "negative": 0.011921784840524197, "neutral": 0.9161433577537537}}, "embedding": [-0.0755283311009407, -0.10813907533884048, 0.0066553629003465176, 0.0199859868735075, 0.10615409910678864, -0.03385678678750992, -0.06915400177240372, -0.008401010185480118, -0.07867977023124695, 0.04994276911020279, -0.022145137190818787, 0.0396307036280632, -0.00840428750962019, 0.03113444894552231, -0.03446248918771744, 0.08681638538837433, -0.05429162457585335, -0.18079452216625214, 0.0017934944480657578, 0.009178586304187775, -0.2962297797203064, 0.004744465462863445, 0.08476722240447998, 0.16855168342590332, 0.11703230440616608, -0.1354285031557083, -0.1304212063550949, 0.17229728400707245, -0.008069091476500034, -0.003245615167543292, 0.029346691444516182, -0.0579567551612854, -0.031071998178958893, -0.025839410722255707, -0.0397881418466568, -0.08247635513544083, -0.07877133041620255, 0.052762534469366074, -0.14003443717956543, 0.11573828011751175, 0.009025870822370052, -0.1549982875585556, -0.18269667029380798, 0.10140346735715866, -0.042051129043102264, -0.07761985808610916, -0.0835305005311966, -0.05731549486517906, 0.09186437726020813, 0.1000782772898674, -0.11940913647413254, -0.14228777587413788, -0.08955347537994385, -0.026567883789539337, -0.024773569777607918, -0.04322955384850502, -0.25418734550476074, 0.02657262049615383, -0.03926040977239609, -0.14762726426124573, -0.015575037337839603, -0.03589417785406113, -0.044820837676525116, 0.09560300409793854, 0.07847894728183746, 0.11561938375234604, 0.06040250137448311, 0.16523921489715576, 0.06134132668375969, -0.049841951578855515, 0.10599163919687271, -0.029015889391303062, 0.01303526759147644, 0.029575267806649208, -0.08922119438648224, 0.09970477968454361, 0.16026988625526428, 0.03110148012638092, 0.06918812543153763, -0.05143573507666588, 0.053730808198451996, 0.0022775710094720125, 0.1807936728000641, -0.12421291321516037, 0.03315883129835129, -0.06930862367153168, 0.014789131470024586, 0.03337763994932175, -0.09251894801855087, -0.048455122858285904, 0.1757616400718689, 0.06961297243833542, 0.004514029249548912, 0.08723804354667664, -0.21813149750232697, -0.029119405895471573, 0.007710185367614031, -0.10166247189044952, 0.00363657483831048, 0.11972711235284805, 0.0217890702188015, 0.0029243805911391973, -0.06315818428993225, -0.028747599571943283, -0.09422506392002106, -0.07237322628498077, -0.04319654032588005, 0.0682189092040062, -0.11715678870677948, 0.03472430631518364, 0.0541222020983696, 0.18108414113521576, -0.003384267445653677, -0.19474634528160095, -0.10592829436063766, 0.21556350588798523, -0.13933716714382172, 0.00891889724880457, 0.05353216081857681, -0.017352471128106117, -0.10923290252685547, 0.033064715564250946, -0.18336942791938782, -0.05995291471481323, -0.01394612342119217, 0.1811354160308838, -0.07570361346006393, 1.5502412151804635e-32, 0.00868945848196745, 0.0004852070997003466, 0.15364478528499603, 0.011481773108243942, 0.02383441850543022, 0.05120978131890297, 0.055334072560071945, -0.016270559281110764, -0.19320635497570038, -0.2662656605243683, -0.07120360434055328, 0.09793552756309509, 0.1330195814371109, -0.24790571630001068, -0.24845553934574127, -0.2078474909067154, -0.011152277700603008, 0.041744012385606766, -0.11312668025493622, 0.042670123279094696, -0.05029628425836563, -0.06138747185468674, -0.14864835143089294, -0.06036610156297684, -0.10214079916477203, -0.0003627928963396698, 0.07265311479568481, 0.1290740668773651, 0.0996776670217514, 0.15038837492465973, -0.16613799333572388, 0.02807767689228058, -0.03663911670446396, -0.17823202908039093, -0.08587518334388733, 0.0374131016433239, -0.09573598206043243, -0.10379593819379807, 0.0984097272157669, -0.12395943701267242, -0.009504279121756554, -0.08568154275417328, -0.11027737706899643, -0.028184035792946815, -0.07490094006061554, 0.018560141324996948, -0.11223011463880539, -0.11183089762926102, 0.060538049787282944, -0.08694570511579514, -0.06752163171768188, -0.011561213992536068, -0.20239652693271637, 0.027482450008392334, -0.045285265892744064, 0.058164652436971664, -0.060768336057662964, -0.0042317756451666355, 0.10474843531847, 0.04919436201453209, 0.269400954246521, 0.057439107447862625, 0.05219043418765068, -0.06470939517021179, -0.07120281457901001, 0.029255256056785583, -0.1145889163017273, -0.1913658082485199, -0.12560713291168213, 0.0619455948472023, 0.024573862552642822, 0.08832476288080215, 0.17877231538295746, -0.06494619697332382, 0.030960863456130028, 0.0563504733145237, -0.02053065598011017, 0.021403666585683823, 0.06520523875951767, 0.29309573769569397, 0.03256405517458916, -0.19283375144004822, 0.0007134267361834645, 0.0029319962486624718, 0.09228584170341492, -0.06243099644780159, -0.008963045664131641, 0.004125496838241816, -0.02909119799733162, 0.0683157816529274, 0.09944064170122147, -0.10577965527772903, 0.0076758526265621185, 0.07766766101121902, 0.049365561455488205, -1.5694839107666305e-32, 0.049761854112148285, 0.0831805169582367, 0.012415502220392227, -0.1027008518576622, -0.03997645154595375, 0.0912509486079216, -0.05092738941311836, 0.06345584243535995, 0.048454031348228455, 0.11285724490880966, 0.049704406410455704, 0.15712153911590576, -0.08153754472732544, -0.042521119117736816, -0.022016268223524094, -0.07350459694862366, 0.11660367250442505, -0.05268208310008049, -0.005633484572172165, 0.02204228937625885, -0.059245578944683075, 0.12789170444011688, -0.0687379315495491, 0.2396787405014038, -0.05644909664988518, 0.11351636052131653, 0.055596306920051575, 0.13315139710903168, 0.07515332847833633, -0.07422414422035217, -0.09269783645868301, -0.038872502744197845, -0.21801474690437317, 0.025983916595578194, -0.02960515208542347, -0.0580911859869957, 0.16842028498649597, -0.07078398764133453, -0.027697116136550903, -0.05549607798457146, 0.034869030117988586, -0.02555806376039982, -0.09341643005609512, 0.13051629066467285, 0.06525803357362747, 0.09994584321975708, 0.014391844160854816, 0.004713212139904499, 0.22372138500213623, -0.050472382456064224, -0.01779424212872982, 0.160194993019104, -0.01765105128288269, 0.09506607055664062, -0.018220840021967888, -0.00869775004684925, -0.08466490358114243, -0.08649892359972, -0.05660751461982727, 0.04432636871933937, 0.037573669105768204, 0.0626554936170578, -0.29868146777153015, -0.07282574474811554, 0.08226436376571655, 0.1763976663351059, -0.018454117700457573, -0.023540174588561058, 0.1316385418176651, -0.03473493456840515, -0.10602308809757233, -0.03511229529976845, -0.060901105403900146, -0.16930334270000458, -0.0414038747549057, 0.15838955342769623, 0.09741547703742981, -0.06440537422895432, -0.13917161524295807, 0.17082560062408447, 0.13932731747627258, -0.1407322734594345, 0.07290966808795929, 0.04831971228122711, -0.05427345633506775, 0.04445129632949829, 0.06843339651823044, -0.05675404891371727, -0.12148063629865646, -0.09440606087446213, 0.008429525420069695, -0.09307222813367844, -0.1431976854801178, 0.13133616745471954, 0.13386774063110352, -1.0023214969123728e-07, 0.07456620782613754, -0.11419985443353653, 0.11500346660614014, 0.00389486295171082, 0.13013818860054016, -0.05043046921491623, -0.014089606702327728, 0.09062156081199646, 0.049652744084596634, 0.222699373960495, -0.10935299843549728, 0.011053003370761871, 0.060510773211717606, -0.07351535558700562, -0.005409426521509886, 0.13493140041828156, -0.09608281403779984, 0.08025385439395905, 0.010918449610471725, -0.0013866224326193333, 0.028790591284632683, -0.048047229647636414, 0.17209012806415558, 0.05287676677107811, 0.008572215214371681, 0.09466763585805893, 0.05817490071058273, 0.11289077997207642, 0.008054633624851704, -0.0621212013065815, -0.040435340255498886, -0.14363563060760498, -0.06142796576023102, 0.21924416720867157, -0.05822772532701492, -0.014073706232011318, 0.13487789034843445, 0.026332257315516472, 0.012526486068964005, 0.08398693799972534, 0.09223571419715881, -0.09444794803857803, 0.06031440198421478, 0.1401921510696411, -0.07792031764984131, 0.06059229373931885, -0.13913363218307495, 0.019654667004942894, 0.07470665872097015, -0.28179335594177246, 0.11133258044719696, -0.1076134741306305, 0.07751350849866867, 0.08949540555477142, -0.101080022752285, 0.10964610427618027, -0.07805965095758438, 0.007862753234803677, -0.0503237321972847, 0.10552617907524109, 0.16422784328460693, -0.19240467250347137, 0.012975440360605717, 0.125374898314476], "changes": {"1wk": 41.534390082695296, "1mo": 3.4391564927213896}}, {"text": "Biotech Stock Roundup: BIOA Down on Study Update, QURE, CRDF Gain on Study Data & More Zacks Equity Research Wed, Dec 11, 2024, 5:55 PM 5 min read In This Article: INCY -0.57% QURE +0.06% It was a busy week in the biotech sector with lots of data readouts. This apart, the key regulatory updates and pipeline news also continued to be in the spotlight. Recap of the Week\u2019s Most Important Stories : BIOA Plummets on Study Data BioAge Labs\u2019 BIOA shares plunged after the company announced that it would discontinue the ongoing mid-stage study of its investigational drug candidate, azelaprag. The STRIDES is a phase II randomized, double-blind, placebo-controlled study of azelaprag as monotherapy and in combination with Eli Lilly\u2019s tirzepatide that planned to enroll approximately 220 individuals with obesity (aged 55 years and older). The study was designed to evaluate the efficacy as measured by body weight reduction and other outcomes, safety, and tolerability of two oral doses of azelaprag (300 mg, once or twice daily) in combination with tirzepatide (5 mg subcutaneous injection once weekly). A monotherapy arm was included to provide additional safety information. BIOA discontinued both arms after liver transaminitis without clinically significant symptoms was observed in some subjects receiving azelaprag. However, no transaminase elevations were observed in the tirzepatide only treatment group. QURE Up on Regulatory Update uniQure N.V. QURE announced that it has reached an agreement with the FDA on key elements of an accelerated approval pathway for AMT-130 in Huntington\u2019s Disease. Shares gained 109.73% on the news. AMT-130 obtained the FDA\u2019s Regenerative Medicine Advanced Therapy (\u201cRMAT\u201d) designation to treat Huntington\u2019s disease. The deal was made at an RMAT meeting with the regulatory body in November 2024. The FDA agreed that the reported data from the ongoing early to mid-stage studies of AMT-130 for Huntington\u2019s disease, compared to a natural history external control, are sufficient to serve as the primary basis for a biologics license application (BLA) for accelerated approval. Furthermore, the regulatory body has agreed that cUHDRS may be used as an intermediate clinical endpoint and that reductions in neurofilament light chain (NfL) measured in cerebrospinal fluid may serve as supportive evidence of therapeutic benefit in the application for accelerated approval. QURE initiated BLA readiness activities and looks forward to further engaging with the FDA in the first half of 2025 to discuss its statistical analysis plan and the technical requirements. CRDF Stock Up on Colorectal Cancer Study Data Cardiff Oncology CRDF announced positive initial data from an ongoing mid-stage study evaluating two doses of its lead investigational candidate, onvansertib (20 mg and 30 mg), in combination with standard-of-care (SOC) chemotherapy to treat first-line RAS-mutated metastatic colorectal cancer (mCRC) patients. The stock surged on the news. Story Continues Initial results from randomized phase II CRDF-004 demonstrated an objective response rate (ORR) of 64% in the 30mg onvansertib dose arm, almost double the 33% ORR observed in the control arm (SOC alone). The 30 mg dose arm also demonstrated a higher ORR than 50% observed in the 20 mg dose arm. Overall, patients treated with onvansertib demonstrated an ORR of 57%. The company also shared spider plots in the press release, which show that patients receiving the 30mg dose of onvansertib with SOC experienced greater tumor size reduction over time compared to those in the control and 20mg dose arms with similar safety profiles for both doses. The combo therapy was also well tolerated in the CRDF-004 study, and no major or unexpected toxicities were observed. Cardiff Oncology expects to share additional clinical updates from the mid-stage study in the first half of 2025. INCY\u2019s Study Meets Goals Incyte INCY announced positive results from the late-stage study on retifanlimab. The phase III POD1UM-304 study is evaluating retifanlimab in combination with platinum-based chemotherapy for the treatment of adults with previously untreated non-squamous and squamous metastatic non-small cell lung cancer (NSCLC) not harboring a driver mutation. Results from the POD1UM-304 study showed a clinically meaningful and statistically significant improvement over chemotherapy alone. Patients in the retifanlimab and chemotherapy combination treatment group achieved a median OS of 18.1 months compared to 13.4 months in the placebo and chemotherapy combination group. The POD1UM-304 study met the primary endpoint of OS and all secondary endpoints in patients with previously untreated metastatic NSCLC. Retifanlimab is marketed as Zynyz by INCY in the United States for Merkel cell carcinoma. In 2017, Incyte entered into an exclusive collaboration and license agreement with MacroGenics, Inc. for global rights to retifanlimab. Incyte currently carries a Zacks Rank #3 (Hold). You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here . GSK Moves With Label Expansion of Nucala GSK plc GSK announced that the FDA has accepted its regulatory filing, seeking the approval of a new indication for Nucala (mepolizumab) in chronic obstructive pulmonary disease (COPD) treatment for review. A decision from the regulatory body is expected on May 7, 2025. GSK\u2019s Nucala is a monoclonal antibody with a novel mechanism of action that targets IL-5, a key messenger protein (cytokine) in type 2 inflammation. Please note that Nucala is already approved in the United States for four IL-5-mediated conditions \u2014 severe eosinophilic asthma (aged 6+), chronic rhinosinusitis with nasal polyps in adults, eosinophilic granulomatosis with polyangiitis in adults and hypereosinophilic syndrome in patients aged 12+. Currently, the drug is not approved for COPD worldwide. GSK\u2019s regulatory filing seeking the approval of Nucala as an add-on maintenance treatment for patients with COPD with an eosinophilic phenotype was supported by positive data from its phase III MATINEE study. Performance The Nasdaq Biotechnology Index has gained 0.17% in the past five trading sessions and Regeneron\u2019s shares have risen 3.86%. In the past six months, shares of MRNA have lost 72.06%. (See the last biotech stock roundup here: Biotech Stock Roundup: BBIO Stock Up on Drug Approval, SAVA, APLT Plunge on Setbacks & More ) Zacks Investment Research Image Source: Zacks Investment Research What's Next in Biotech? Stay tuned for more pipeline updates. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report GSK PLC Sponsored ADR (GSK) : Free Stock Analysis Report Incyte Corporation (INCY) : Free Stock Analysis Report BioAge Labs, Inc. (BIOA) : Free Stock Analysis Report uniQure N.V. (QURE) : Free Stock Analysis Report Cardiff Oncology, Inc. (CRDF) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CRDF", "date": "2024-12-11T14:55:00+00:00", "sentiment": {"score": 0.27661287784576416, "confidence": 0.5664905309677124, "probabilities": {"positive": 0.5664905309677124, "negative": 0.28987765312194824, "neutral": 0.14363181591033936}}, "embedding": [-0.07489858567714691, -0.06307776272296906, -0.07316293567419052, -0.02575553208589554, -0.18218132853507996, -0.007062659133225679, -0.13953809440135956, 0.3049420118331909, -0.013478366658091545, 0.08735249936580658, 0.011969324201345444, 0.1341513693332672, 0.056367047131061554, 0.06554851680994034, -0.0649365484714508, 0.02296832762658596, 0.05484364181756973, 0.021939249709248543, -0.07603342831134796, 0.016342703253030777, -0.045436158776283264, 0.04578565061092377, 0.1074618548154831, 0.09973926097154617, -0.046863384544849396, -0.0519656240940094, -0.13226377964019775, -0.08632577955722809, -0.036165233701467514, -0.04801371321082115, 0.01373434066772461, 0.11849579960107803, 0.024503622204065323, -0.16057804226875305, -0.07595241069793701, -0.06459568440914154, -0.07414093613624573, -0.06354820728302002, -0.11975400149822235, 0.0005088932812213898, 0.016006700694561005, 0.008559633046388626, -0.1836046278476715, 0.03295320272445679, -0.07403750717639923, -0.15933048725128174, -0.09610036015510559, 0.007741381414234638, 0.037822313606739044, 0.16295593976974487, -0.09601790457963943, -0.12530365586280823, 0.08394847065210342, 0.09301172196865082, 0.025682270526885986, -0.013023888692259789, -0.019650232046842575, -0.07932737469673157, -0.07142303884029388, 0.11857886612415314, -0.052238985896110535, 0.04772317409515381, 0.0064438325352966785, 0.007258102297782898, 0.09003273397684097, 0.06862777471542358, -0.07812085002660751, -0.10267224162817001, 0.025499634444713593, -0.10913164913654327, 0.014096801169216633, -0.14572706818580627, 0.030093662440776825, 0.08165097236633301, -0.05778791755437851, 0.022147851064801216, 0.058529406785964966, 0.13033726811408997, 0.056292496621608734, -0.027018122375011444, -0.06617674976587296, 0.04008404165506363, 0.057167697697877884, -0.0823364183306694, 0.046004101634025574, -0.013474796898663044, -0.06651853024959564, 0.23073989152908325, -0.04656202718615532, 0.12953732907772064, 0.07008662819862366, -0.024908725172281265, 0.0236424021422863, -0.0241119135171175, 0.024507230147719383, -0.062164150178432465, -0.09502135217189789, -0.12418807297945023, 0.008632507175207138, -0.06532296538352966, 0.09518831968307495, 0.01751639135181904, -0.04239306598901749, -0.016552768647670746, -0.13891522586345673, -0.12229438126087189, 0.08588586002588272, -0.041884422302246094, -0.015535777434706688, 0.05642002075910568, -0.054899848997592926, -0.015415254980325699, 0.10462488234043121, 0.022341780364513397, -0.1378578245639801, 0.285635381937027, -0.04275386780500412, 0.0860959142446518, 0.14077596366405487, 0.04449573904275894, -0.03729955106973648, 0.046096522361040115, 0.0933884009718895, -0.16230285167694092, 0.15532520413398743, 0.11314671486616135, -0.05736950784921646, 8.504510610367241e-33, 0.02943143993616104, 0.022673074156045914, -0.12509673833847046, 0.015651684254407883, -0.016192808747291565, 0.08275321871042252, 0.015220767818391323, 0.10718096792697906, 0.046664923429489136, -0.15429483354091644, 0.0012116346042603254, -0.05297653377056122, 0.07343068718910217, 0.02631981112062931, -0.11133906245231628, 0.004583832807838917, 0.021407853811979294, 0.07139813899993896, -0.007742632180452347, 0.08479489386081696, 0.05715024098753929, -0.08132664859294891, -0.04418084770441055, 0.014402997680008411, -0.08273544907569885, 0.12431201338768005, -0.16568075120449066, 0.10798877477645874, -0.10153713822364807, 0.049799494445323944, -0.07765445858240128, -0.0022457046434283257, -0.0517130121588707, -0.16265790164470673, -0.06773535162210464, -0.09871730953454971, -0.02205759659409523, -0.0408150888979435, -0.050767216831445694, 0.1308443397283554, 0.09491712599992752, 0.0704708993434906, 0.00659150630235672, -0.07805375009775162, 0.13190284371376038, 0.029388973489403725, -0.1159108579158783, 0.010161379352211952, 0.04110007733106613, -0.001086696982383728, -0.054810017347335815, 0.04286053776741028, 0.01048910804092884, -0.06531724333763123, -0.01958216167986393, 0.04991234093904495, -0.15941840410232544, 0.0011405106633901596, 0.0404830127954483, 0.0894952118396759, 0.06662862002849579, 0.1428872048854828, -0.001233140006661415, 0.05551324784755707, -0.12793323397636414, 0.09349876642227173, -0.11440714448690414, -0.14509370923042297, -0.14013594388961792, 0.15927329659461975, -0.015213100239634514, -0.08012282848358154, 0.11125515401363373, 0.09366779029369354, 0.10627859830856323, -0.09958714246749878, 0.03761046379804611, 0.06489269435405731, -0.039303556084632874, -0.023628447204828262, -0.011061606928706169, 0.07704436779022217, -0.04037344828248024, 0.07489679753780365, 0.02197885699570179, -0.012856917455792427, -0.035530462861061096, 0.026000529527664185, -0.06175682321190834, -0.05590631812810898, 0.08254635334014893, -0.058809321373701096, -0.1228053867816925, 0.12538352608680725, 0.10704249143600464, -9.420975964778207e-33, -0.06355307996273041, 0.10321751981973648, -0.005573725327849388, -0.13920581340789795, 0.0654311329126358, 0.04713510349392891, 0.06298670172691345, -0.0559137761592865, 0.15716761350631714, -0.17910920083522797, 0.09330922365188599, 0.04550154507160187, -0.07813853025436401, -0.059296395629644394, -0.06832588464021683, 0.15535525977611542, 0.007857415825128555, -0.10218065977096558, -0.05355769395828247, 0.05669684708118439, 0.01688040792942047, 0.0950288325548172, -0.1066121906042099, -0.005083837080746889, 0.12955370545387268, 0.013273179531097412, 0.037556689232587814, 0.04847652092576027, 0.1049603745341301, -0.019204983487725258, -0.02123730443418026, 0.021630696952342987, -0.24227461218833923, -0.02732507325708866, -0.06688772141933441, -0.037063803523778915, -0.009843725711107254, -0.13121967017650604, -0.1224919855594635, -0.036055583506822586, 0.16109204292297363, 0.08689475059509277, -0.042469803243875504, 0.011955397203564644, -0.015521621331572533, -0.04281557723879814, 0.024294666945934296, -0.15105989575386047, 0.1367429494857788, 0.04101583734154701, 0.009645242244005203, -0.0041930703446269035, 0.13310997188091278, 0.13418059051036835, -0.004269685596227646, -0.10260757803916931, 0.04732196778059006, -0.048799339681863785, -0.13603739440441132, -0.03829396143555641, 0.04478522390127182, 0.13819071650505066, -0.04318973422050476, -0.012480616569519043, 0.08586452901363373, 0.016090966761112213, 0.14101773500442505, -0.08062419295310974, 0.02040679194033146, -0.06711285561323166, -0.09208890795707703, -0.08419837057590485, 0.05646380037069321, 0.010968509130179882, 0.05422747880220413, 0.13552843034267426, -0.023651031777262688, -0.10527956485748291, -0.13511613011360168, -0.12986688315868378, -0.03477275371551514, -0.1205112412571907, -0.014743846841156483, -0.0007131006568670273, 0.08302249014377594, 0.0951080173254013, -0.15072882175445557, -0.08426231145858765, -0.023450227454304695, 0.038908958435058594, -0.028144819661974907, -0.08255313336849213, -0.10551139712333679, 0.090755894780159, 0.03939530998468399, -1.0085089741096454e-07, 0.12644198536872864, -0.1584002524614334, -0.10392304509878159, 0.013958021067082882, 0.005828901194036007, 0.0021681501530110836, -0.09671462327241898, 0.062178753316402435, -0.05184698849916458, 0.06354677677154541, 0.0023416709154844284, 0.26399949193000793, -0.01864580065011978, 0.10516125708818436, -0.05724503844976425, 0.11334019899368286, 0.02348235622048378, 0.03390447795391083, -0.01474814023822546, 0.03260407969355583, -0.14587578177452087, -0.12809722125530243, -0.021483339369297028, -0.1180906891822815, -0.023104306310415268, -0.03342142328619957, 0.0460180938243866, 0.06686073541641235, 0.05345044657588005, -0.0668187215924263, 0.01476946659386158, -0.0316975973546505, 0.0726701021194458, 0.02157328836619854, -0.01854262314736843, -0.10820861905813217, 0.19003687798976898, 0.05839943885803223, -0.03868529573082924, 0.19222155213356018, 0.053089722990989685, 0.05162542313337326, 0.04455775022506714, 0.023433303460478783, 0.03353540226817131, -0.07446686178445816, -0.09767722338438034, -0.03707101568579674, 0.09523319453001022, -0.04087801277637482, 0.047226011753082275, -0.006282215937972069, 0.14016219973564148, -0.003704432863742113, 0.0025186582934111357, 0.09125778079032898, -0.0008901699911803007, -0.12167220562696457, -0.0452665314078331, 0.028333444148302078, 0.07690738141536713, -0.1485530138015747, 0.19730979204177856, -0.06921765208244324], "changes": {"1wk": 21.351343601441467, "1mo": -2.432436525081473}}]